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1. INTRODUCTION 
 
 
1.1. Basic principles of NMR spectroscopy 
 
 
NMR spectroscopy is the study of molecular structures through measurement of 
the interaction of a radio frequency electromagnetic radiation with a collection of 
nuclei immersed in a strong magnetic field.1 The nuclei of all elements carry a 
charge. When the spins of the protons and neutrons comprising these nuclei 
are not paired, the overall spin of the charged nucleus generates a magnetic 
dipole along the spin axis. The intrinsic magnitude of this dipole is a 
fundamental nuclear property called the nuclear magnetic moment µ. The 
symmetry of the charge distribution in the nucleus is a function of its internal 
structure and if this is spherical (i.e. analogous to the symmetry of a 1s 
hydrogen orbital), it is said to have a corresponding spin angular momentum 
number of I = 1/2, of which examples are 1H, 13C, 15N, 19F, 31P etc. In quantum 
mechanical terms, the nuclear magnetic moment of a nucleus with I = 1/2 can 
align with an externally applied magnetic field of the strength B0 in only 2I+1 
ways, either reinforcing or opposing B0. The energetically preferred orientation 
has the magnetic moment aligned parallel with the applied field (spin +1/2) in 
contrast to the higher energy anti-parallel orientation (spin -1/2). The rotational 
axis of the spinning nucleus cannot be oriented exactly parallel (or anti-parallel) 
with the direction of the applied field B0 but must preces about this field with an 
angular velocity given by the expression:  
ωo = γ B0                                                                           (1)   
 (ωo - Larmor frequency in Hz)   
The constant γ is called the magnetogyric ratio and relates the magnetic 
moment µ and the spin number I for any specific nucleus:  
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γ = 2piµ/hI                                                                        (2)   
(h is Planck's constant)   
For a single nucleus with I = 1/2 and positive g, only one transition is possible 
(∆I = 1, a single quantum transition) between the two energy levels.   
NMR is all about how to interpret such transitions in terms of chemical structure. 
If angular velocity is related to the frequency by ωo = 2piν, then  
ν = γ B0/2pi                                                                      (3)   
It follows that the proton NMR transitions (∆I = 1) have the following energy:   
              h ν = ∆E = h γ B0/2pi                                                         (4)   
For a proton γ = 26.75 x 107 rad T-1 s-1 and B0 ~ 2T, ∆E = 6 x 10-26 J, which is so 
small that a Boltzmann distribution has to be considered. The relative 
populations of the higher (n2) and lower (n1) energy levels at room temperature 
are given by the Boltzmann law:  
n2/n1 = e-∆E/kT ~ 0.99999.                                                   (5)   
For NMR, this means that the probability of observing a transition from n1 to n2 
is only slightly greater than that for a downward transition, i.e. the overall 
probability of observing absorption of energy is quite small. This relationship 
also explains why a larger B0 favors sensitivity in NMR measurements, 
increasing the difference between the two Boltzmann levels, and why NMR 
becomes more sensitive at lower temperatures. 
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1.2. Relaxation processes 
 
 
When the sample is inserted into a magnetic field B0, the Boltzmann distribution 
of spins occurs between the energy levels. In order to move to a higher energy 
level, energy in the form of electromagnetic radiation needs to be supplied. 
Electromagnetic radiation in the radiofrequency (RF) range is of the correct 
energy to initiate this excitation. RF pulses can be applied to generate a 
magnetic field B1 perpendicular to B0. This causes the spins to flip away from 
the z-axis and gain x- and y-components (Figure 1). The precessing about the 
z-axis in the xy-plane generates a detectable alternating RF field. At the end of 
the applied RF pulse the nuclear spins return to their ground state by interacting 
with the surrounding environment through a process called spin-lattice 
relaxation T1. As the spins realign with B0, the current produced by rotation in 
the xy-plane diminishes. The time necessary for disappearance of this current 
can be measured and is termed the spin-spin relaxation time T2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Behavior of the net magnetization vector Mz upon exposure to an 
RF pulse. 
 
T1 relaxation occurs due to magnetic field fluctuations at the Larmor frequency 
brought about by the random motions of molecules in the surrounding medium 
B0 Mz
YX
Z
B1
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(lattice). These molecules in motion each have magnetic moments, and the 
movement of these moments leads to a magnetic ‘noise’ that encompasses a 
broad frequency range including the Larmor frequency. Magnetic noise at the 
Larmor frequency will stimulate transitions to the lower energy state. 
T2 relaxation occurs via fluctuations of a magnetic field caused by the random 
motion of molecules resonating at the same frequency. Fluctuation in the 
individual proton spins leads to a loss of phase coherence in the xy-plane with 
no net loss of energy from the system. Spin-spin relaxation is additionally 
affected by dephasing arising from bulk inhomogenities in B0. 
 
 
1.3. Magnetic resonance imaging (MRI) 
 
 
 MRI is a diagnostic scanning technique based on principles of NMR. It 
measures the signal from the hydrogen nuclei of water, which is modified by the 
chemical environment. NMR spectroscopy measures the characteristics of any 
hydrogen nuclei depending on their position in the molecule. Instead of 
obtaining information about chemical shifts and coupling constants, MRI gives 
spatial distribution of the intensity of the water proton signal in the volume of the 
body. This signal intensity depends essentially on three factors: the density of 
proton spins in a given volume, the longitudinal and transverse relaxation times 
T1 and T2 of these spins.2,3 Using different RF pulse sequences, image intensity 
can be weighted with respect to T1 or T2. 
Spin-lattice relaxation time T1 and spin-spin relaxation time T2 may be 
shortened considerably in the presence of paramagnetic species. Therefore the 
targeted application of paramagnetic compounds can be used to increase 
contrast, working as contrast agents (CA). CA’s increase the signal intensity of 
the tissue containing them by increasing the longitudinal and/or transverse  
relaxation rates (1/T1 or 1/T2) using their unpaired electrons to facilitate spin 
transfer. The diamagnetic (1/T1,2d) and paramagnetic (1/T1,2p) contributions to 
the relaxation rates of such solutions are additive: 
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1/ T1,2obs. = 1/ T1,2d  + 1/ T1,2p                                  (6) 
  
The paramagnetic contribution to the relaxation rate is linearly proportional to 
the concentration of the paramagnetic species: 
 
1/ T1,2obs. = 1/ T1,2d + r1,2 [M]                                      (7) 
 
where M = paramagnetic substances, r1,2 = proton relaxivity (s-1mM-1).  
For a predetermined image acquisition time, a shorter relaxation time results in 
a stronger signal because a larger population of the sample relaxes in that 
given time. This allows increased concentration-dependent contrast, and hence 
finer spectral resolution. The addition of a contrast agent results in an increased 
relaxation rate of the surrounding nuclei that appear as a bright spot of 
increased intensity in T1-weighted images or as a region of decreased 
brightness in T2-weighted images. MRI contrast agents are thus classified as 
positive or negative, T1 or T2, contrast agents. T1 agents are usually preferred 
as a positive contrast enhancement is often more easily detected than a 
negative one. An ideal MRI contrast agent would have as many unpaired 
electrons as possible. It may be simply a substance4 (i.e. molecular oxygen), a 
stable radical5 (i.e. nitroxide radical) or a metal ion6 (i.e. transition metal ions). 
Paramagnetic metal ions do show a suitable effect, which depends on the 
number of unpaired electrons in the ion. Paramagnetic ions of various transition 
metals like Fe3+, Mn2+ and rare earth metals of the lanthanide series like Gd3+, 
Dy3+ etc. as revealed in Table 1, have received great attention as 
magnetopharmaceuticals.7,8 There are more transition metals and lanthanide 
metals with unpaired spins, but for the metal to be effective as a relaxation 
agent the electronic spin-relaxation time must match the Larmor frequency of 
the protons. This condition is met best for Mn2+, Fe3+ and Gd3+.9,10 
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Table 1.  Electronic configuration of some paramagnetic metals 
 
Atomic 
number 
Ion Electronic 
configuration 
3d 4f Bohr 
magneton 
25 Mn2+ [Ar]3d54s0 ↑ ↑ ↑ ↑ ↑ 
 
5.9 
26 Fe3+ [Ar]3d54s0 ↑ ↑ ↑ ↑ ↑  5.9 
63 Eu3+ [Xe]4f66s0  ↑ ↑ ↑  ↑  ↑  
↑  __ 
6.9 
64 Gd3+ [Xe]4f76s0  ↑ ↑ ↑  ↑  ↑  
↑  ↑ 
7.9 
66 Dy3+ [Xe]4f96s0  ↑↓ ↑↓ ↑  ↑  
↑  ↑  ↑ 
5.9 
 
 
The prominent feature of gadolinium(III) is that seven unpaired electrons 
generate a symmetric S-state with a very slow electronic spin relaxation rate.11 
Thus Gd3+ exhibits the strongest effect of all elements on the longitudinal 
relaxation time T1. 
It is fortuitous that water exchanges quite readily on Gd3+ aqua complexes. The 
rate of exchange between aqua ligands on octadentate-chelated Gd3+ is 
approximately 3 x 106s-1, which allows thousands of water molecules to 
transiently coordinate to a single ion on the MRI time scale. Thus, the effect of 
the metal fragment on relaxation times is widespread, and only low 
concentrations (0.1-0.3 mM/kg) are necessary to be effective.12-18 At the proper 
concentration, Gd3+ contrast agents enhance T1 relaxation preferentially, 
thereby causing increase in signal on T1-weighted images. Since T1 weighted 
protocols in MRI have rapid pulse sequences, Gd3+ chelates are the favored 
agents. Moreover, they do not significantly affect the bulk magnetic 
susceptibility of the tissue compartment in which they are localized, thereby 
resulting in minimal macroscopic field inhomogenities and image artifacts. 
Dysprosium is another interesting paramagnetic lanthanide that exhibits 
Introduction 
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predominant r2 susceptibility effects (1.8 times that of Gd3+) and relatively low T1 
relaxivity (1/40 of Gd3+) but it is more toxic than gadolinium.19 The transition 
metal and paramagnetic lanthanide ions suitable as MR contrast agents are all 
potentially toxic at or near doses required for NMR relaxation changes. A major 
difficulty in the development of any of the paramagnetic metals as CA has been 
to diminish this toxicity to clinically acceptable levels. Gadolinium remains in the 
body several days after intravenous administration. This toxicity can only be 
reduced by coordinating the metal to ligands that are too obstinate to be 
displaced by water. One or two coordination sites must be open for water 
molecules, to allow inner sphere spin transitions, or transitions between the 
metal nuclei and a ligand to which they are directly bound. Owing to its large 
size, gadolinium tends to favor high coordination numbers in aqueous media. 
Currently, all Gd3+- based chelates approved for use in MRI are eight to nine-
coordinate complexes. This allows the design of various chelators according to 
the final target. Moreover, the choice of a proper ligand is very important to 
ensure that gadolinium does not dissociate from the complex in the body in the 
presence of phosphate, citrate, transferrin and other endogenous chelating 
substances. The dissociation of a complex generally leads to a higher degree of 
toxicity stemming from the free metal ion or free chelating ligand.20 
 
 
1.4. Effects of contrast agents on water proton relaxation 
 
 
 CA’s affect water magnetization by two primary ways: direct relaxivity and 
indirect susceptibility effects. Susceptibility effects dominate in large 
superparamagnetic particles and can be much stronger than relaxivity effects in 
certain situations. They may be useful even without complete quantization. 
Susceptibility induced relaxations are due to long-term interactions. For the 
most of the small gadolinium based CA’s direct relaxivity is dominated. The 
origin of paramagnetic relaxation enhancement generated by paramagnetic 
lanthanide complexes can be divided into three components: inner sphere water 
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(directly coordinated to the metal), secondary sphere water (molecules are on 
the hydrophilic side of the complex) and outer sphere water (bulk water) 
 (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Schematic depicting the interactions of water molecules with 
gadolinium(III)-based contrast agent. 
 
 
The inner sphere contribution is due to the interaction between the Gd3+ 
electron spins and the water protons in the first coordination sphere of the metal 
transmitted to the bulk via chemical exchange of the inner sphere protons. Bulk 
solvent molecules diffusing around the paramagnetic centre also experience the 
paramagnetic effect. The relaxation mechanism arising from this random 
translational diffusion is defined as outer sphere relaxation.21,22 For the 
paramagnetic chelates both inner-sphere and outer-sphere components are 
comparable in magnitude and the final effect is additive, whereas for 
macromolecular complexes, the inner-sphere contributions tend to dominate the 
relaxation.  
N
N N
N
O
O
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O
O
O
O
O
O
OH2
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water (IS)
O H
H
2nd sphere
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O H
H
O
H
H
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H
H
H
O H
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The relaxation of current clinically approved agents is due to approximately 60% 
inner sphere and 40% second and outer sphere effects.23 The overall 
contribution to the relaxivity can be divided into the following terms: 
 
r1 = r1
IS
 
+ r1
SS + r1
OS                                                                 (8) 
 
where IS, SS and OS are inner sphere, second sphere and outer sphere water 
molecules. Inner sphere effects can be modified whereas outer sphere effects 
cannot easily be affected. The inner sphere term can be broken down further as 
in equation (9), where c is the molal concentration of the contrast agent, q is the 
number of bound water molecules per paramagnetic ion, τm is the mean lifetime 
of the water molecules in the inner sphere environment, and 1/T1m is the 
longitudinal proton relaxation rate. The term 1/T1m is composed of a dipole-
dipole term (DD) and a scalar term (SC) (10).  
 
 
                                                                                                          (9) 
 
 
                                                                                                         (10) 
 
 
 (11) 
 
 
 
 
As the scalar term becomes negligible at magnetic field strengths above 10 
MHz and since most clinical experimental MR images are acquired at field 
strengths higher than 10 MHz, the scalar term is not an important factor in 
proton relaxation, thus 1/T1m is essentially determined by the 1/T1DD term (11). 
The dipole-dipole term is modulated by reorientation of the nuclear spin vectors 
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with respect to the electron spin vector, changes in orientation of electron spin, 
and the rate of the water exchange. The theory of T1 contrast agents 
demonstrates that numerous parameters affect relaxivity. The parameters q, 
rGdH, τm, τr, and T1e can be adjusted by altering the chemical environment 
around the paramagnetic ion.24 By increasing the value of q, the relaxivity of the 
agent will increase. However increasing q above two will most likely result in 
increased toxicity due to decreased stability of the complex. A decrease in rGdH 
will lead to an increase in relaxivity. Decreasing the term τm will allow more 
water molecules to be affected by the gadolinium(III) ion resulting in an increase 
in relaxivity. If the value of τm is decreased too much, the relaxivity of a complex 
will begin to decrease because the lifetime of the water molecules bound to the 
gadolinium(III) ion will not be long enough to influence the relaxation of the 
protons of the water molecule. By optimizing the value of τr or T1e, the relaxivity 
of the contrast agent will be increased. There is an interdependence of the 
terms τm, τr, and T1e. For most of the small molecule gadolinium (III) complexes, 
τr is the limiting of the three variables. As the value of τr becomes optimized the 
variables τm and T1e begin to influence the relaxivity of the contrast agents. The 
residence lifetime of the protons τm modulates the efficiency of the chemical 
exchange from the inner sphere of water molecules to the bulk. This process 
can occur in two ways, exchange of the protons independently of the exchange 
of the entire water on which it resides, or the exchange of water molecule 
itself.25 
Introduction 
 13  
1.5. Types of contrast agents 
 
 
As it was shown before, according to major effects they produce on images, 
contrast agents may be broadly divided into positive contrast agents or T1 
agents (appearing bright on MRI) or negative contrast agents or T2 agents, 
appearing dark on MRI. The question of which type of contrast enhancement to 
choose for a particular application depends on the specific organ or disease 
suspected and the pulse sequence used. 
  
 
1.5.1. Non - lanthanide based contrast agents 
 
 
Iron 
 
 
When exposed to a magnetic field, the resultant permanent magnetic moment 
of the iron particles is very large. Magnetic particulates of various iron oxides 
are now being used as exogenous agents for enhancing 1/T2 preferentially at 
imaging fields.26 The most common form of iron oxide used is magnetite, which 
is a mixture of Fe2O3 and FeO. Iron oxide particles (diameter = 5-200 nm) are 
said to possess superparamagnetic properties if the “magnetic” ions are 
mutually aligned.27 For solutions or suspensions of sufficiently large 
paramagnetic or ferromagnetic particles (greater than or equal to 25 nm 
diameter), the paramagnetic contributions to the relaxation rates satisfy 1/T2 
much better than 1/T1 at typical imaging fields.  
Depending on the overall size of the crystal, the iron oxides are broadly 
classified into two categories. Those with diameter more than 50 nm are called 
superparamagnetic iron oxide (SPIO) particles. As with its use as an oral 
contrast agent, SPIO causes marked shortening of the T2 relaxation time 
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resulting in a loss of signal in the liver and spleen with all commonly applied 
pulse sequences.28,29 Organically coated iron oxide crystallites with diameters of 
5-50 nm (‘nanoparticles’) are called ultra-small SPIO (USPIO) and are potential 
magnetic contrast enhancing agents for the reticule endothelial system. USPIO 
with crystal sizes less than 10 nm have been reported to have excellent T1-
enhancement properties.30-33 Iron particle based agents generally lead to a 
much larger increase in 1/T2 and are best visualized on T2 weighted scans.34  
 
 
Manganese(II) chelates 
 
 
The manganese ion (Mn2+) is an excellent T1 contrast agent for MRI. 
Manganese chloride is commercially available as Lumen-Hance (Bracco) for 
such applications. The paramagnetic manganese ions are able to substitute 
partially for calcium, which rapidly fluxes in and out of synaptic terminals 
regulate neurotransmitter release.35 Topical administration of MnCl2 solution via 
intravitreal injection to neurons in mice leads to enhancement of contrast along 
the respective pathways, thereby permitting visualization of neuronal 
connections.36 Mn2+ mesoporphyrin, a lipophilic compound, was investigated as 
a potential hepatobiliary contrast agent.37 Aime and coworkers have developed 
an oxygen-tension responsive contrast agent based on the redox switch of 
Mn(II/III)-Porphyrin complexes which have had success in the visualization of 
tumors because these complexes tend to localize in tumors.38 Manganese 
dipyridoxyl diphosphate (MnDPDP) was shown to be useful in establishing the 
diagnosis of acinar cell carcinoma, a rare pancreatic exocrine neoplasm.39 
MnDPDP, which specifically labels liver tumors over healthy liver tissue, helps 
to determine if surgery on hepatic tumors is a viable option.40-42 The manganese 
porphyrin (ATN-4T) accumulates in subcutaneous tumors in rabbits while 
rapidly clearing from surrounding tissues to yield images with enhanced tumor 
intensity.42 HOP-8P, a manganese porphyrin complex demonstrated sustained 
tumor enhancement of squamous cell carcinoma in mice.46 
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1.5.2. Lanthanide metal chelates  
 
 
According to the chemical structure lanthanide containing CAs are divided in 
two groups: acyclic and macrocyclic agents. Usually they are based on two 
most widely used chelators for the complexation of Gd3+, 
diethylenetriaminepentaacetate (DTPA) and 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetate (DOTA).47,48 Chelates with a higher stability constant have 
been developed and used successfully.49-52 
 
 
Gd-DTPA and its derivatives 
 
 
Diethylenetriaminepentaacetic acid (DTPA) is a readily available octadentate 
ligand. As shown in Chart 1, the Gd-DTPA family constitutes a large and widely 
used group of MRI contrast agents.53 DTPA chelates are easily derivatized. 
Various complexes have been designed and evaluated using thermodynamic 
stability, rates of excretion, toxicity, lipophilicity, biodistribution, and percent 
change in MR signal intensity as critera keeping Gd-DTPA as the gold standard. 
The complexes are anionic, and therefore, quite water-soluble (usually to about 
0.5–1.0 M). The formation constant of Gd-DTPA (log K) is 10. The ionic 
chelates are also hyperosmolar with respect to body fluids and some of their 
side effects may be attributed to this property. This causes the intravascular 
fluids to osmotically absorb water and blood at the vessels in which it resides.  
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No Molecule R1 R2 and R2’ R3 R4 
a DTPA -OH -H -OH -H 
 
b DTPA- 
BMA 
-NHCH3 -H -NHCH3 -H 
c DTPA- 
BMEA 
-NH(CH2)2-OCH3 -H -NH(CH2)2OCH3 -H 
d BOPTA -OH -H -OH CH2-O-
CH2-C6H5 
e EOB- 
DTPA 
-OH R2=-H 
R2’=-CH2-C6H4-O-Et 
-OH -H 
f MS- 
325L 
-OH R2=CH2PO3HC6H9(Bz)2 
R2’=-H 
-OH -H 
 
Chart 1.  Some important diethylenetriaminepentaacetate (DTPA) analogs: a) DTPA; 
b) bismethylamide of DTPA (DTPA-BMA); c) bismethoxy- ethylamine 
derivative of DTPA (DTPA-BMEA); d) benzyloxymethyl substituted DTPA 
(BOPTA); e) ethoxybenzyl substituted DTPA (EOB-DTPA); f) MS-325. 
 
 
As the complexes are distributed through the circulatory system, this effect 
becomes negligible. The median lethal doses (LD50) of these complexes in rats 
are 10 mM/kg body weight. Typical counterions to these complexes include 
sodium and N-methylglucaminium. There is little difference between these ions 
in terms of toxicity (LD50) or solubility, but N-methylglucaminium is usually 
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preferred, as it can be safely administered even in patient with hypernatremia. 
Gd-DTPA (Gadopentetate Dimeglumine Magnevist™, Berlex Laboratories,  
Wayne, NJ) was the first intravenous ionic MR contrast agent to be approved by 
the FDA in mid-1988 for human use.54,55 Gd-DTPA is distributed in the 
intravascular and extracellular fluid spaces, does not cross an intact blood brain 
barrier (BBB), and is excreted rapidly (within 2-3 h of administration) by 
glomerular filtration. After injection, half-life of Gd-DTPA in blood is ~20 minutes. 
Being a structurally simple complex, it is not site-specific, and is most commonly 
used as a contrast agent for systemic MRI; e.g., to search for tumors with 
compromised BBB or the metastasis lesions of tumors.  
Since Gd3+ and Ca2+ have approximately the same ionic radius, and Ca2+ is 
prominent in physiological settings, there is danger of metal substitution, which 
would release free Gd3+ into the system. In fact, this does happen to some 
extent, which explains the detectable residual Gd3+ after 14 days. However, 
replacement of a carboxylate binding moiety with an amide group increases the 
ligand binding affinity by a factor of ~10/amide group, and this is the advantage 
of Gd-DTPA-BMA, the bismethylamide of Gd-DTPA or gadodiamide 
(Omniscan™, Sanofi-Winthrop Pharmaceuticals, NY) as shown in Chart 1b. 
Gadodiamide is a nonionic complex with two-fifths of the osmolality of Gd-
DTPA.56 This agent distributes non-specifically throughout the plasma and leaks 
rapidly from blood into the interstitial space with a distribution half-life of about 5 
min.57 In Gd-DTPA-bis(methoxyethylamide) or Gadoversetamide, the two 
carboxylate binding moieties of DTPA are replaced with methoxyethyl 
substituted amide groups (Chart 1c). OptiMARK (Gd-DTPA-BMEA; 
Mallinckrodt Inc., St. Louis, MO) is a sterile, nonpyrogenic aqueous solution of 
gadoversetamide, a nonionic gadolinium chelate, developed for use as an 
intravenous MR contrast agent.58  
The hydrophobic benzyloxymethyl substituent of Gd-BOPTA Chart 1d or 
Gadobenate Dimeglumine (MultiHance™) renders it more susceptible to 
hepatocellular uptake and excretion into the bile ducts, gall bladder, and 
intestines than the parent complex, Gd-DTPA. However, it is not so hydrophobic 
as to be completely absorbed into fatty tissue. Therefore, it is useful as an 
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extracellular fluid agent, such as Magnevist (Gd-DTPA) or ProHance 
(Gadoteridol) or as a liver-specific agent to target the liver and bile ducts, such 
as Teslascan (mangafodipir) or iron oxides (e.g., Endorem). Gd-BOPTA is a 
positive MR contrast agent for intravenous application that couples specific, 
long lasting enhancement of magnetic resonance signal intensity in the liver 
parenchyma with the plasma kinetics of agents targeted to the extracellular fluid 
space.59-61 In comparison to other gadolinium-chelates it has a nearly 2-fold 
increased relaxivity due to weak protein binding with plasmatic macromolecules. 
It also has potential to become a useful contrast agent for MRA as 
demonstrated in the volunteers. A related compound, gadolinium-ethoxybenzyl-
diethylenetriamine pentaacetic acid as shown in Chart 1e, (Gd-EOB-DTPA) is 
absorbed to an extent of approximately 5% by the liver and has been used as 
an intrabiliary contrast agent for depicting biliary structures.62,63 
The large hydrophobic diphenylcyclohexyl moiety in MS-325 (Chart 1f) 
(Gadophostriamine Trisodium) or Angiomark™, a gadolinium based MRI blood 
pool agent,64 allows it to bind strongly to serum proteins (especially albumin). As 
depicted in Cart 1f. The hydrophilic phosphodiester group in MS-325, placed in 
between the hydrophobic group and the chelate allowed for high reversible 
albumin binding affinity. MS-325 is highly protein bound (80%-96% in human 
plasma) after injection, which decreases the concentration of free drug in 
serum, resulting in its retention in blood for a longer time (~1 h) than most other 
Gd3+ contrast agents (~30 – 180 sec). The longer stay of the complex in blood 
allows one to obtain more acquisitions, and thus higher resolution images with 
better vascular signal enhancement than otherwise possible. MS-325 exhibits a 
relaxivity approximately 6-10 times that of Gd-DTPA. MS-325 is the prototype 
blood pool agent for use in the imaging of blood vessels and blood flow in 
patients with cardiovascular disease, including peripheral vascular disease. 
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The DO3A family 
 
 
Owing to a lower entropy loss in chelation, macrocyclic compounds release less 
free Gd3+ into their physiological surroundings than do their linear acyclic 
counterparts. 1,4,7,10-tetraazacyclododecane-1,4,7-tricarboxylic acid (DO3A) 
(Chart 2g), is itself not an ideal chelating agent for Gd3+ contrast agents, but it 
serves as a starting point for the synthesis of numerous derivatives since a 12-
atom ring appears to be ideal for MRI contrast agents.65 The Gd chelate of 
DOTA, marketed as Dotarem™ (Chart 2h), is an extracellular (systemic) MRI 
contrast agent.66,67 Gd-DOTA is as safe a contrast agent as Gd-DTPA and has 
similar diagnostic efficacy. It targets no specific anatomical site or physiological 
function. The major distinct advantage of Gd-DOTA over Gd-DTPA lies in its 
lower relative viscosity so that it diffuse faster and pass through the injection 
needle more quickly for a given applied pressure, thereby minimizing patient 
discomfort because a burning sensation due to osmolality is felt otherwise.68 
 
N
N N
N
OO
O
OH
HO
HO
R
 
 
 
 
 
 
 
Chart 2.  1,4,7,10-tetraazacyclododecane-1,4,7-triacetate (DO3A) and its 
derivatives: g) DO3A; h) DOTA; i) HP-DO3A; j) DO3A-butrol. 
 
The applications of Gd-HPDO3A (Chart 2i) are generally parallel to those of Gd-
DOTA, but are more often for visualization of the brain, spinal cord and 
No Molecule R 
g DO3A -H 
h DOTA -CH2COOH 
i HP-DO3A -CH2CH(OH)CH3 
j DO3A-butrol -CH(CH2OH)-CH(OH)-CH2OH 
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cerebrospinal fluid than for tumor detection. Its derivative, the Gd3+complex of 
10-(2,3-dihydroxy-1-hydroxymethylpropyl)-1,4,7,10tetraazacyclododecane1,4,7-
triacetic acid (Chart 4j) Gd-DO3A-butrol or gadobutrol, or Gadovist™) is a 
neutral Gd-chelate for use as an extracellular contrast agent in similar clinical 
settings as the parent moiety.69 An i.v.-LD50 of 23 mM/kg in mice combined with 
a comparatively high T1-relaxivity (5.6 l/mM per s at 0.47 T and 6.1 l/mM per s 
at 2 T) in plasma promises a high margin of safety. Gadoteridol (ProHance, 
Squib Diagnostics, Princeton, NJ) is another low osmolar, nonionic contrast 
agent.70,71 In human intracranial metastatic disease, administration of 0.3 
mM/kg Gadoteridol (Gd-HPDO3A) (Chart 2i) has permitted detection of 
additional lesions not visualized at 0.1 mmol/kg. 
 
 
Smart contrast agents 
 
 
To image extra or intracellular activities, researchers are tailoring the agents so 
that they are 'turned on' only in the presence of a threshold concentration of a 
specific molecule.72 The relaxivities of these designer magnetopharmaceuticals 
are dependent on certain biochemical variables. These smart ‘bioactivated 
agents’ sense their biochemical environment either through enzyme-induced 
relaxivity changes or changes in the levels of a biomarker metabolite. The 
concept is to utilize injectable compounds of high tissue specificity with the 
ability to provide information of the physico-chemical environment, when 
activated in response to a change in some biochemical event. The choice of the 
biochemical target, the chelates and the physiological/pathological situation are 
critical deterministic parameters in the design, development and applications of 
such agents in imaging the biological functions. 
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Enzyme sensitive contrast agents 
 
 
Synthesis of 1-(2-(β-galactopyranosyloxy)propyl)-4,7,10-tris (carboxy methyl)-
1,4,7,10-tetraazacycododecane) gadolinium (Gd-DO3A-gal) which consists of a 
DOTA type ligand that occupies either of the nine binding sites on gadolinium 
and replacing one of the acid group by a galactopyranose residue positioned to 
block the remaining coordination site on the gadolinium ion from water, was 
reported to  selectively enhance MRI signal from cells or tissues containing β-
galactosidase enzyme.73-74 These are cage-like molecules (a gadolinium ion 
inside a chemical scaffold or molecular basket) wherein the access of nearby 
protons of water to gadolinium in chelated CA is physically blocked with an 
enzyme substrate (galactopyranose residue at the open co-ordination site of 
gadolinium) amounting to ‘latching the basket’. Upon the production of the 
targeted enzyme, which can clip the molecular cage open and dissolve the 
shield on the gadolinium, the activity of CA will be fully turned on.  
These agents have two states of activity, weak and strong. The effect is just half 
as the galactose group coordinates to the Gd3+ lowering the final relaxivity, and 
is turned on in the presence of specific enzymes or other biologically important 
molecules that cleaves the galactopyranose group. Specifically tailored marker 
enzyme, β-galactosidase react with specific substrates to open the cage by 
dissolving galactopyranose (amounting to ‘lifting the lid’) and thereby activating 
the CA. Thus, in the presence of the right enzyme the barrier dissolves and due 
to free interaction of water with gadolinium, MRI signal doubles in strength. This 
physiologically sensitive MRI CA opens up a wealth of new avenues of study, 
even including the in vivo imaging of gene expression. Meade’s group has 
demonstrated that such agents light up special biological action and it is even 
possible to monitor gene transfer and to trace the cellular expression of specific 
genes75. Anelli and coworkers have synthesized a DTPA derivative which can 
detect carbonic anhydrase.76 The gadolinium complex contains a sulfonamide 
group in place of one of the carboxylic acid arms of the DTPA, helping it to  
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selectively target the enzyme carbonic anhydrase. Upon binding to the enzyme, 
the relaxivity increases significantly due to an increase of the rotational 
correlation time (τr) caused by binding to the large enzyme. Nivorozhkin and 
coworkers prepared an agent that is sensitive to the presence of human 
carboxypeptidase B (a thrombin-activatable fibrinolysis inhibitor (TAFI)), which 
has been implicated in thrombotic disease.77 TAFI cleaves a trilysine masking 
group attached to the agent exposing an aromatic functional group. This 
aromatic group has a high binding affinity for human serum albumin (HSA). The 
contrast agent binds HSA leading to an increase in τr resulting in an increase in 
relaxivity. This event is known as a receptor-induced magnetization 
enhancement (RIME). The trilysine chain makes this agent a pro-RIME agent 
because the trilysine chain inhibits interaction with HSA. Bogdanov and 
coworkers prepared a peroxidase activatable agent.78 This agent consists of a 
gadolinium(III) chelate linked to benzene-1,2-diol that acts as a monomer. In the 
presence of peroxide, the monomers are oligomerized yielding a threefold 
increase in relaxivity due to an increase in τr.  
Perez and coworkers have utilized the difference in relaxivity between solitary 
CLIO particles and those in close proximity to other cross-linked iron oxide 
(CLIO) particles to detect DNA cleaving agents.79 Two strands of 
complementary DNA are each conjugated to a CLIO particle. When the 
complementary strands bind, the CLIO particles from each strand come into 
close proximity to each other. Upon cleavage of the double strand by a DNA-
cleaving agent, the two CLIO particles become separated leading to a 
detectable change in relaxivity. Utilizing a similar mechanism, Zhao and 
coworkers have developed a protease sensitive MRI contrast agent.80 With this 
agent, the strong interaction between biotin and avidin is exploited. A molecule 
of biotin is conjugated to each side of a peptide that is cleaved by proteases. 
CLIO particles coated with avidin are exposed to the bi-biotinylated peptides. In 
the presence of protease specific for the peptide, the CLIO particles will not 
aggregate; however, in the absence of protease, aggregation of the CLIO 
particles will occur resulting in an increase in relaxivity. Up today this agent has 
only been used in vitro. 
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pH sensitive CA 
 
 
Fe(III) meso-tetra(4-sulfonatophenyl)porphine (Fe-TPPS4) has been 
investigated as a potential pH-sensitive NMR proton image contrast agent. 
Relaxation rates (1/T1 and 1/T2) of water protons were measured as a function 
of pH and concentration of Fe-TPPS4 in phosphate-buffered isotonic saline. 
The transverse relaxation rates (1/T2) did not change appreciably at pH > 6.0. 
The longitudinal relaxation rates (1/T1) increased from pH 7.75 to 5.75.81  
Aime explored the chemical exchange saturation transfer (CEST) properties of 
a series of lanthanide(III) complexes (Ln = Eu, Dy, Ho, Er, Tm, Yb) with the 
macrocyclic DOTAM-Gly ligand, which is the tetraglycineamide derivative of 
DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid). These 
complexes possess two pools of exchangeable protons represented by the 
coordinated water and the amide protons. Yb-DOTAM-Gly displays the most 
interesting CEST properties when its amide N-H resonance (16 ppm upfield 
H2O signal) is irradiated. Up to 70% suppression of the water signal is obtained 
at pH 8. As the exchange rate of amide protons is base-catalyzed, Yb-DOTAM-
Gly results to be an efficient pH-responsive probe in the 5.5-8.1 pH range.82 
The low molecular weight gadolinium chelate diethylentriaminepentaacetic 
acide bis-methylamide (GdDTPA-BMA) encapsulated within pH-sensitive 
liposomes is introduced as a novel type of pH-sensitive paramagnetic contrast 
agent. The in vitro relaxometric properties of the liposomal gadolinium chelate 
were shown to be a function of the pH in the liposomal dispersion and the 
membrane composition. Only a minor pH-dependency of the T1 relaxivity (r1) 
was observed for liposomal GdDTPA-BMA composed of the unsaturated lipids 
dioleoyl phosphatidyl ethanolamine (DOPE) and oleic acid (OA). On the other 
hand, the r1 of GdDTPA-BMA encapsulated within saturated dipalmitoyl 
phosphatidyl ethanolamine/palmitic acid (DPPE/PA) liposomes demonstrated a 
strong pH-dependency. At physiological pH and above, the r1 of this system 
was significantly lowered compared to that of non-liposomal gadolinium chelate, 
which was explained by an exchange limited relaxation process. A 
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tetrasubstituted derivative of 1,4,7,10-tetraazacyclododecane83 with amide 
coordinating groups and extended noncoordinating phosphonate groups forms 
a complex with Gd3+, which contains one slowly exchanging inner-sphere water 
molecule. The water proton relaxivity of the complex was found to be highly pH 
dependent. Protonation of the noncoordinating phosphonate groups appear to 
catalyze prototropic exchanges of the bound water protons, thereby providing a 
mechanism for enhanced water contrast below pH 7. Another approach is 
based on a microenvironmental responsive polyion complex in the form of a 
mixture of two polymers. The complex exhibits a fifty percent increase in 
relaxivity upon decreasing pH from 7.0 to 5.0. The mechanism of how the 
complex works is unknown; however, it is detectable in the presence of tumors 
in mice but inot in the absence of tumors.84,85 Hovland and coworkers have 
developed a pH-sensitive contrast agent which is a DO3A derivative with a 
tertiary amine-containing side arm.86 The side arm amine contains two long 
alkyl chains. When the amine is protonated (pH 3-6) the relaxivity is low. Upon 
deprotonation (pH 8-10), the agents form colloidal aggregates due to the higher 
lipophilicity of the deprotonated complex. The aggregation causes an increase 
in τr and a subsequent increase in relaxivity of 142%. 
 
 
Metal ion sensitive contrast agents 
 
 
Several metal ions (e.g. Ca2+, Zn2+) are essential or beneficial to life while 
others, such as lead, cadmium or mercury, are highly detrimental. Many 
diseases have been associated in a way or another to altered metal ion 
concentrations in the body. Deficiencies can be as damaging as overloads. 
Copper deficiency has been associated to anemia while excess copper can 
lead to Wilson’s disease (liver cirrhosis). Anemia may also be caused by a lack 
of iron and overload of this same metal ion is connected to thalassemia and 
siderosis.87 In vivo determination of the metal ion distribution is thus highly 
desirable and progresses have been made towards the design of MRI contrast 
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agents sensitive to the concentration of some metal ions such as Ca2+, Mn2+, 
Fe2+ and Zn2+. 
An iron-sensitive contrast agent was synthesized by Aime and coworkers 
functionalizing DO3A with salicylate moieties as shown in Schema 1.88 Upon 
addition of iron(III), the gadolinium(III) DTPA-salicylate complexes bind to the 
iron ions via the salicylate functional groups. This binding yields an increase in tr 
and relaxivity.  
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Schema 1.  Iron sensitive contrast agent. 
 
 
Zinc is a key component of many enzymes, transcription factors, and synaptic 
vesicles. Hanaoka and coworkers have developed a series of contrast agents to 
detect zinc(II) (Schema 2).89,90 Their design consists of gadolinium(III) DTPA 
modified with pyridine ligands and carboxylic acids. In the absence of zinc(II), 
water is bound to the gadolinium(III) ion. In the presence of zinc(II), the 
carboxylic acid and pyridine moieties coordinate to zinc(II) thus restricting the 
access of water to the gadolinium(III) ion. This decrease in q yields a decrease 
in relaxivity in the presence of zinc(II).  
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Schema 2.  Zinc sensitive contrast agent. 
 
 
Li et al (1999) synthesized a calcium-responsive agent, DOPTA-Gd, using 
calcium-chelating BAPTA fluorophores (Schema 3).91,92 The relaxivity of the 
complex is controlled by the presence or absence of the divalent ion Ca2+. In 
the presence of low concentraions of calcium, the aromatic iminoacetate group 
may coordinate in some fashion to the gadolinium ion, maintaining low (outer 
sphere) relaxivity.By structurally modulating inner-sphere access of water to a 
chelated Gd3+ ion, a substantial and reversible change in T1 could be affected 
upon the addition of Ca2+ and not other divalent ions. After Ca2+ is bound to 
DOPTA-Gd, the molecule undergoes a substantial conformational change that 
opens up the hydrophilic face of the tetraazacyclododecane macrocycle.  
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Schema 3.  Calcium sensitive contrast agents. 
 
 
This change dramatically increases the accessibility of the chelated Gd3+ ion to 
the bulk solvent. As the concentration of calcium approaches micromolar levels, 
the EGTA binds calcium, possibly releasing the Gd3+ coordinated iminoacetates 
and increases (doubles up) relaxivity by more than doubling the number of 
inner-sphere water molecules. With the swing of the calcium concentration from 
low to high to low, these smart CA switches from off to on to off, thereby acting 
as reversible smart contrast agent. This may have interesting implications for 
monitoring of brain functions or nerve activities based on calcium dependence 
or detection of turning on and off of cell signals by secondary messenger like 
calcium. It has been shown that the paramagnetic properties of lanthanides can 
be exploited to obtain information on specific parts of a protein surface. Owing 
to the high affinity of coordinatively unsaturated lanthanide complexes for 
oxygen donors, carboxylate groups can be used as preferential targets for the 
interaction. The DO3A ligand is particularly useful in these studies, as it 
coordinates lanthanides in a heptadentate fashion, leaving two sites available 
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for exogenous donors. Gd3+-DO3A is thus a valuable semi-selective probe for 
clusters of negative charges on the protein surface.93 
 
 
1.6. Contrast agents in neuroscience 
 
 
In the neuroimaging field MRI has evolved as a very useful tool that offers 
quantitative assessments of tissue characterization in studies of cerebral 
neoplasm,94  ischemic events,95 inflammations and demyelinating diseases,96 
thereby, yielding insights towards both diagnosis and prognosis, as well as for 
monitoring therapeutic response. If the MRI experiment is done while a mental 
task is given to a subject, a so-called functional magnetic resonance image (or 
fMRI) image is generated. The fMRI is based on the increase in cerebral blood 
flow to the local vasculature accompanied by increase in oxygen level and 
glucose consumption that follows neural activity in the brain. The blood-oxygen-
level-dependent (BOLD) magnetic resonance signal used in functional imaging 
of the brain reflects the loss of oxygen from hemoglobin, causing its iron to 
become paramagnetic, which influences the magnetic field experienced by 
protons in surrounding water molecules.97-99 The fMRI is currently the most 
widely used method for brain mapping and studying the neural basis of human 
cognition.100-103 On such an image one can see how different tasks activate 
different parts of the brain relatively specifically. By listening to music, for 
example, a specialized area in the so-called auditory cortex along the sides of 
the brain shows increased signal.104 Vision activates a region in the back of the 
brain (the occipital cortex), localized precisely to regions of the visual field.105 
Touch brings increased signal along the side of the brain, particularly in the side 
of the brain opposite to the part of the body that is touched106 and movements 
activate regions in the front and the top of the brain in cortex specialized for 
motor control.107 It has been shown that the BOLD contrast mechanism directly 
reflects the neural responses elicited by a stimulus and that it is most closely 
correlated with the local field potentials, implying that activation in a given area 
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is often likely to reflect the incoming input and the local processing in that area 
rather than the spiking activity.108-113 Unfortunately BOLD fMRI is not fully 
sufficient for the study of neural networks, because of a local blood flow the 
BOLD hemodynamic signal is the indirect indicator of neural activity, and an 
associated time lag broadens the response and also causes the problems in 
spatial colocalization. 
 
 
1.7. Aim of the project 
 
 
The aim of this project is to develop contrast agents that are ‘smart’ biochemical 
functional markers rather than anatomical agents. The markers are supposed to 
detect neuronal activity in real time and translate it into changes in MR contrast. 
This would permit a direct visualization of neural activation independent of the 
state of the vascular system. A series of the markers can be used to follow the 
changes in the neuronal signals (pH, metal ions concentrations, enzymes).  
Currently no suitable extracellular agents are available for examining 
concentration changes of ions or molecules involved in the neural signaling 
process. However, some works,89-92 which were described previously in detail, 
appear to be useful models for designing agents for these requirements. 
Ca2+ ions play a central role in the process by which the electrical potential 
across the membrane of presynaptic nerve terminals regulates the release of 
neurotransmitter substances into the synaptic cleft. The release occurs when a 
voltage-dependent Ca2+ channel in the presynaptic membrane opens, thus 
permitting an influx of Ca ions and diffusion of Ca2+ in cytoplasm, followed by 
binding of Ca2+  at some cytoplasmic site that triggers the exocytotic release of 
quanta of neurotransmitter. Although the general role of Ca2+ as a presynaptic 
messenger is well supported, many important specifics of its action remain to be 
resolved.111-115 
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The goal is the development of contrast agents, which are sensitive to local 
extracellular pH or calcium ions concentration changes during the neuronal 
activation. 
 
 
 
 
Figure 3.  Ca2+ ions in the synaptic cleft. 
 
 
At the beginning novel acyclic bifunctional or macrocyclic ligands should be 
developed. The compounds should have parts containing gadolinium, to act as 
a contrast agent, and sensors which are responsive for the contrast changes 
during the changes in the chemical environment. On this purpose the new 
macrocyclic chelators with the different types of donor atoms (carboxylates or 
phosphonates) can be used for the design of the selective classes of specific 
“smart” pH / calcium-sensitive contrast agents. The monophosphonate 
containing part of the molecule can act as pH sensor, because of their 
sensitivity to changes of the pH of the solutions. The 
aminobis(methylene)phosphonate containing macrocycles should act as 
calcium sensors with the high affinity toward the calcium. The different length of 
the phosphonate side chain can be used to adjust the complexing properties of 
the complexes and fine tune the sensitivity toward the calcium. All agents first 
should be evaluated by means of in vitro MR measurements in simulated 
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physiological conditions and characterized by physico-chemical methods (such 
as potentiometric titration, NMR spectroscopy and NMRD profiles). Subsequent 
in vivo characterization, in rats, should examine their distribution, half-time and 
toxicity. Those experiments should provide more information about the 
behaviors of complexes in order to optimize their final structures.
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2. GENERAL PART 
 
 
2.1. Synthesis of acyclic bifunctional chelates and their 
lanthanide complexes 
 
 
2.1.1. Introduction 
 
 
Aminocarboxylic acids are ideal to chelate metal ions. Particularly stable 
chelates are formed with metals from the alkaline earth, transition and rare 
earth metal series. Bifunctional ligands can bind tightly to the metal ion forming 
a chelate while at the same time bearing a second functionality which confers 
upon it desirable chemical, physical and/or biological properties. Such physical 
properties of the chelators differ depending on the purpose of the metal chelate. 
The metal chelates which act as a contrast media for NMR imaging or general 
purpose X-ray imaging, require high water solubility, viscosity and osmolality of 
a formulated drug solution as close as possible to those of in vivo conditions. 
Furthermore functionalized chelates, or bifunctional coordinators, are capable of 
being covalently attached to bigger molecules such as biopolymers and 
supports.116,117 Aminocarboxylic acid chelating agents have been known and 
studied in the literature for several years.118 Typical of the aminocarboxylic 
acids are ethylenediaminetetraacetic acid (EDTA), ethylene glycol bis(2-
aminoethyl ether)-N,N,N'N'-tetraacetic acid (EGTA), diethylenetriamine 
pentaacetic acid (DTPA) as well as 1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-
tetraacetic acid (BAPTA) (Chart 3). 
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Chart 3.  Aminocarboxylate as chelating agents a) EDTA, b) EGTA, c) 
DTPA, d) BAPTA.  
 
 
The functionalized aminocarboxylates (a – d) have been applied as a dyes for 
optical imaging119. For example a series of compounds based on the BAPTA 
were developed as contrast agents for optical trace of metal ions like Ca2+, Mg2+  
and Zn2+).120-123  
Although, a series of the metal chelators were developed until now, the design 
of new chelating agents with new complexing properties is of current interest. 
The new bifunctional chelating agents described in Chart 4 can be used to 
chelate or sequester metal ions. The complexes, because of the presence of 
the moiety -NH2, can be attached to functionalized polymeric supports, or 
preferably covalently attached to antibodies or antibody fragments. For example 
complexes with gadolinium themselves can be used as contrast agents in MRI. 
The ability of the ligands to chelate calcium can be used for the design of the 
calcium sensitive dyes and relaxometric probes. 
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Chart 4.  Bifunctional chelating agent. Z= -NO2, -NH2. 
 
 
2.1.2. Synthesis of the ligands 5, 11 and complexes 6a, b; 12a, b 
 
 
The nitro and amino derivatives of the ligands 5 and 11 were synthesized by 
two different ways according to Schemes 4 and 5. The alternative route 
depicted in Scheme 5 was developed after the non satisfactory reduction of the 
nitro group in compound 5, which gave very poor yields in the catalytic 
hydrogenation with platinum oxide or palladium catalysts. 
According to Schema 4, the synthesis of the ligand 5 started from the 
commercially available nitroisophtalic acid (1) which was treated with excess of 
ethylendiamine to give compound 3. Compound 3 was alkylated in the presence 
of K2CO3 with tert-buthyl ester of the bromoacetic acid resulting in 4, which was 
deprotected by TFA in DCM. Recrystalization from hot methanol gave the final 
ligand 5 as a yellow powder in 78% yield. 
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Scheme 4. Synthesis of the acyclic complexes 6a, b; i) HCl/ MeOH; ii) 
ethylendiamine, r. t., 12h; iii)  t-Butyl bromoacetate, K2CO3, 
CH3CN;  iv) DCM, TFA; v) H2O, GdCl3 x H2O (6a) H2O, EuCl3 x 
6H2O (6b).  
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Scheme 5. Synthesis of the acyclic complexes 12a, b; i) CBz, K2CO3 ; ii) 
ethylendiamine, r. t., 12h; iii)  t-Butyl bromoacetate, K2CO3, 
CH3CN; iv) H2, Pd\C, DCM, TFA; v) H2O, GdCl3 x H2O (12a) H2O, 
EuCl3 x 6H2O (12b). 
 
 
The amino derivative 11 was synthesized starting from dimethylester of 
aminoisophtalate 7. The aminogroup was protected using chlorobenzoformate 
(CBz). Compound 8 was treated with ethylenediamine and alcylated with tert-
buthyl ester of bromoacetic acid by a similar way as it was done for compound 
5. Hydrogen reduction in the presence of Pd/C catalyst of 10 and deprotection 
of the tert-butyl groups with TFA in DCM resulted in compound 11, which was 
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recrystallized from hot methanol to give the final ligand in the 72% overall yield. 
The 13C {1H} NMR spectrum of 11 is presented in Figure 4 and contained all the 
resonances according to the symmetry of the molecule. The substituted 
aromatic carbon atoms can be distinguished from the unsubstituted ones by the 
chemical shifts and the decrease of the peaks intensity because of the longer 
relaxation times of the non-proton-bearing carbons which was also supported 
by DEPT spectrum of the ligand. 
 
Figure 4.  13C{1H} NMR spectrum of the compound 11. 
 
 
Complexation with lanthanides was preformed by stirring the ligands 5 and 11 
(1.0 eq) with the corresponding lanthanide chlorides (0.9 – 1.0 eq) in water 
solutions at r.t. for 12 h at pH 5.0 – 5.5. A low pH of the solutions is preferred to 
avoid precipitation of the metals in the form of their hydroxides. After filtration 
through a 0.2 mm syringe filter complexes 6a, b and 12a, b were obtained.  
The main drawback of the synthesized complexes is their solubility. The 
compounds are poorly soluble in water and in most of the organic solvents at r.t. 
This makes it not only difficult to obtain relaxometric data it is also a drawback 
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for later application as CA. This effect was not obtained by the complexation of 
ligands 5 and 11 with the other metals (Ca2+, Mg2+, Zn2+, Cu2+). 
 
Relaxivity studies 
 
 
Relaxivity studies of the complexes were preformed at a 300 MHz vertical 
imaging magnet, r.t. (~ 21oC) and pH 7.4 (potassium salt of 3-(N-morpholino)-
propanesulfonic acid (KMOPS) buffer). Four different concentrations of 6a were 
prepared (0.1mM, 0.2mM, 0.35mM and 0.5mM) and the relaxivity was 
calculated as the slope of the graph in the Figure 5. The relaxivity of compound 
6a was found to be 4.5 s-1mM-1. The measurements of the relaxivity were also 
preformed in the presence of different metal ions in artificial cerebrospinal fluids 
(ACSF). The results show that there are no changes of the relaxivity observed 
even after the addition up to 10 eq of calcium chloride. This means that the 
gadolinium complexes are relatively strong and no demetalation of the 
complexes in the presence of high amounts of other metals is observed.  
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Figure 5.  Relaxivity rate versus concentration of complex 6a 
(300 MHz and 25 oC). 
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Conclusions 
 
 
In conclusion, two derivatives of acyclic bifunctional chelating agents based on 
the nitro and amino isophtalic acid were synthesized. T1 relaxivity rates of the 
compounds were determined in the presence of up to 10 eq of calcium ions. It 
was shown that the excess of calcium does not affect on the T1 relaxation times 
of the complexes. Precipitation of the complexes was observed during the 
complexation with lanthanides which is the biggest drawback in the application 
of the compounds as relaxation agents. That can be an effect of dimerization or 
polymerization during the complex formation. Similar behavior for the acyclic 
benzyl containing compounds was mentioned in the works of Raymond.124 
Further modifications of the complexes, such as introduction of hydrophilic 
poly(ethylene)glycols or solubilizing dendrimers, are needed to make them 
more attractive as a relaxometric probes for the MR imaging.125 Complexation 
of the ligands 5 and 11 with Ca2+, Mg2+, Zn2+ and Cu2+ does not show any 
precipitation. The ligand 11 due to the presence of the amino group can be 
used as building block for the synthesis of the specific MRI contras agents. 
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2.2. Synthesis and characterization of DO3A based 
mono(alkylphosphonate) complexes as potential pH 
sensitive contrast agents 
 
 
2.2.1. Introduction 
 
 
pH is one of the important factors for the design and development of innovative 
exogenous “smart” CAs that are responsive to changes in their 
microenvironment. Phosphonate containing ligands seem to be a promising 
building block in the design and synthesis of “smart” contrast agents for MRI, 
which are sensitive to changes of the pH. Phosphonates form hydrogen bonds 
with the surrounding water molecules which are sensitive to changes of the 
acidity of solutions. Consequently phosphonates were introduced into 
macrocyclic complexes (Chart 5). Two molecules were reported by Aime’s 
group (Chart 5a and b), where phosphonate and carboxylate derivatives of 
macrocyclic complexes are compared.126-129 It was suggested that the relaxivity 
of the phosphonate containing derivatives which increase at low pH, was due to 
the protonation of the phosphonates. This results in an increase of the number 
of water molecules in the inner sphere of the complexes. However that can also 
lead to a drastic decrease of the stability of the complexes. Formation of ternary 
complexes with carbonates from CO2 of the air at basic pH has been suggested 
as a reason for the relaxivity changes in carboxylate complexes. It also was 
shown, that the presence of two phosphonate moieties decreases the number 
of water molecules in the inner sphere, but they can increase the second 
hydration sphere of the complexes.  
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Chart 5.  Phosphonate containing macrocyclic complexes. 
 
 
As an example it was found that compound a in the Chart 5 has no water 
molecule in the inner sphere, but its relaxivity is comparable with that of the 
DOTA derivative with one water coordinated to gadolinium. The phosphonates 
initiate the formation of second sphere water molecules, which leads to an 
increase of relaxivity. 
Sherry and coworkers described a molecule with amidophosphonate moieties 
(Chart 5b). First in vitro results were presented in 1999 which showed that 
relaxivity changes by changes of the pH in the physiological range.130 Recently 
the possibility for in vivo application was demonstrated by the determination of 
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the pH of tumor tissue. pH maps with improved spatial resolution were obtained 
compared to the MR spectroscopic methods used before.131 
The groups from Prag and Brno introduced the methylphosphonate derivatives 
of DO3A (Chart 5d). A single crystal X-ray analysis was preformed and physico-
chemical characteristics were described, which showed that the phosphonate of 
the pendant arm is complexing to gadolinium.132,133 The complex exists as a 
mixture of two isomers SAP (square antiprisma) and TSAP (twisted square 
antiprisma) which contains one water molecule in the inner sphere. Moreover 
the residence life time of the water molecule in the inner sphere of the complex 
depends on pH which is probably due to the domination of one of the isomers at 
different pH. No visible changes of relaxivity versus pH are observed.  
On the bases of these literature data phosphonate containing macrocyclic 
compounds with protected (18) and unprotected (16) propylphosphonate 
moieties were synthesized (Scheme 6). The motivation was to study the 
dependence of the length of the phosphonate side chain on the complexing 
properties (by comparison with DO3AMP and DO3AEP in Chart 5 (d and e)). In 
addition the investigation of the effect of the charge of the complexes on the 
relaxivity with the aim to get a significant change of the MRI contrast by 
changes of the pH was performed. 
 
2.2.2. Synthesis of the ligands and complexes 
 
 
The ligands 16 and 18 were synthesized according to Scheme 6. Alkylation of 
the tert-butyl ester of DO3A134 (14) with the diethyl ester of 
bromopropylphosphonic acid in presence of 1.5 eq of potassium carbonate in 
acetonitrile gave the protected phosphonate ligand 15. For compound 16 a two 
step deprotection was performed, first trimethylbromosilan was used to remove  
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Scheme 6.  Synthesis of the macrocyclic phosphonate containing complexes 
(17a, b; 19a, b); i) t-Butyl bromoacetate, NaHCO3, CH3CN; ii) 
Diethyl(3-bromopropyl) phosphonate, K2CO3, CH3CN; iii) 
(CH3)3SiBr, DCM, TFA; iv, vi) H2O, GdCl3 x H2O (17a; 19a ), H2O, 
EuCl3 x 6H2O (17b; 19b) v) DCM, TFA. 
 
the ethyl groups of the phosphonates followed by TFA cleavage of the tert-butyl 
groups of the carboxylates. Two times recrystalization from diethyl ether and 
acetone gave clean 16. The different types of recrystalization lead to the 
successful remove of excess TFA. The deprotection was followed by NMR 
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spectroscopy. Compound 18 was obtained after selectively deprotection of 15 
with a TFA / DCM mixture. The same procedure as for compound 16 was 
followed to remove the rest of the TFA. 
The number of resonances and their chemical shifts in the 13C{1H} and 1H NMR 
spectra agree with the symmetry of the molecules (Figure 6). The most 
characteristic features are two resonances in the ratio 1:2 in the low field area, 
related to the absorption of the carboxylates, and doublets of the CH2-PO3H2 
moieties (11) in the 13C{1H} NMR spectrum of the phosphonates (24.4 ppm, 1JPC 
= 134.7 Hz)). 
 
 
 
 
Figure 6. 13C{1H} NMR spectra of the compound 16.  
 
 
Stock solutions of the metal ions with known concentrations were prepared from 
the chloride salts of the corresponding metals. The exact concentrations were 
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determined by complexometric titration with a standard solution of the disodium 
salt of ethylenediaminetetraacetic acid (EDTA). The complexes were prepared 
by stirring of the mixtures of the corresponding stock solutions and the ligands 
16 and 18, respectively, in a ligand : metal ratio of 1 : 0.9. Finally the complexes 
were filtered and lyophilized. The xylenol test was preformed to insure that there 
are no free metal ions in solution (see experimental part).135  
In the mass spectra of 17b and 19b all peaks related to the mass of the [M+H]+ 
complexes are present. For the compounds 17a and 19a seven gadolinium 
isotopes are observed in the mass spectra of complexes. 
 
 
2.2.3. Physico-chemical characteristics of the ligands and 
complexes 
 
Potentiometric studies of the ligands and complexes 
 
 
The acidobasic and complexing properties of the newly synthesized ligands 16 
and 18 were studied by means of glass electrode potentiometric titrations. In 
order to follow the effect of the pendant arm on the acidobasic and complexing 
properties of the new macrocyclic ligands, the DO3A ligand was also included 
for comparison. 
 
Determination of protonation constants 
 
 
The protonation constants of the macrocyclic ligands 16 and 18 were studied at 
25 °C and 0.1 M ionic strength adjusted adding sodium chloride in order to 
compare the experimental values with those reported in literature (Scheme 7). 
The fully deprotonated species of the macrocyclic ligands form stable 
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complexes with sodium ions (e. g. log KNa = 2.2 – DO3A, 4.03 – DOTA, 4.77 – 
DO3AMP136 (Chart 5d)). The same phenomena, but less pronounced can be 
seen for potassium salts applied as inert electrolyte. They also form complexes 
but with reduced stability compared to the analogous sodium ones. As a 
consequence of this fact, the first protonation constant of the ligands is 
decreased more for electrolytes which form more stable complexes with the 
cation of the salt. Therefore the protonation of macrocyclic ligands is studied in 
tetramethylammonium chloride (TMACl) as inert electrolyte to adjust a constant 
ionic strength of the solution (Table 2).  
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Scheme 7. Protonation of the compound 16. 
 Table 2. Logarithmic valuesa) of protonation constants of DO3A, DOTA, DO3AMP, 16 and 18b)  
Ligand Log Kp,1 log Kp,2 log Kp,3 log Kp,4 log Kp,5 Σ log Kp, n (n = 4) Reference 
DO3A 11.19 9.48 4.21 3.35 ---- 28.23 This work 
DO3A 11.59 9.24 4.43 3.48 --- 28.74 147,148 
DO3A 11.55 9.15 4.48 --- --- --- 147, 148 
DO3A 10.51 9.08 4.36 --- --- --- 147,148 
DO3A 10.72 9.51 4.40 4.00 --- 28.63 149 
DO3A 12.46 
(11.24c)) 
9.49 4.26 3.51 1.97 29.72 139 
DO3A 11.96e) 9.66 4.23 3.51  29.36 150 
DOTA 11.73 9.40 4.50 4.19 --- 29.82 147 
DOTA 11.14 9.50 4.61 4.30 --- 29.55 147, 148 
DOTA 9.37 9.14 4.63 3.91 --- 27.05 147, 148 
DOTA 11.34 9.90 4.60 4.00 --- 29.84 149 
DOTA 11.74  9.76 4.68 4.11 2.37 30.29 (27.36c)) 139 
        
DO3AMPc) 13.83 
(10.05c)) 
10.35 6.54 4.34 3.09 34.37 (27.83d)) 136 
DO3AEPb) 10.06 10.11 6.71 4.38 3.42 34.68 (27.97e)) This work 
16b) 11.09 9.94 7.17 4.00 2.82 35.02 (27.85e)) This work 
18b) 9.37 9.45 4.13 2.94d) --- 25.89 This work 
        
 
a)For log Kp,I  the standard deviation ≤ 0.04 log K unit; b)t = 25 °C, I = 0.1 M NaCl (otherwise the medium is stated in parenthesis); 
c)measured at I = 0.1 M TMACl, corrected for sodium ion complexation (log KNa = 2.2 – H3DO3A, 4.03 – H4DOTA, 4.77 – H5DO3AMP); 
d)estimated value; e)the value of overall protonation constant calculated without protonation constant of phosphonic pendant arm; 
f)determined by 1H NMR spectroscopy 
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On contrary, the first high protonation constant of the ligand in 
tetraalkylammonium salts can not be observed with potentiometric 
methods and therefore some values which appeared in literature are 
questionable (Table 2).  
The most probable values seem to be those determined by means of NMR 
spectroscopy or glass-electrode potentiometry where the correction for 
liquid-junction potential in alkaline pH range was taken into account (Table 
2). Thus the recommended protonation constants for DOTA are those 
published recently137,138 and therefore  the values for DO3A determined in 
the same manner are acceptable.139 The sodium complex formation is 
more pronounced for the DOTP and DO3AMP ligands (Chart 5a and d) in 
which the phosphonate pendant arm is capable to stronger bind to 
sodium.140 In the case of compounds 16, 17a, 18 and 19a, the protonation 
constants were determined in sodium chloride solutions for several 
reasons. Firstly, the experimental conditions should be close to conditions 
in vivo, and, secondly, they overcome the problems associated with 
obtaining the highest protonation constants. In addition, knowing the 
stability constant of the sodium complexes, allows a correct calculation of 
the protonation constants. This has been demonstrated in the case of 
DO3A where the experimental values are in good agreement with 
literature data (Table 2).139  
The protonation constants of the ligands 16 and 18 together with the 
values for some analogous ligands are presented in Table 2.132,133 The 
step sequence of ligand protonation was studied for DO3AMP (Chart 5d) 
by 31P and 1H NMR spectroscopy and it was found that two protons are 
bound to nitrogen atoms while their location depends on the number of 
protons of the protonated species. In addition, it was found that there is a 
strong hydrogen interaction between the oxygen atom of the phosphonic 
pendant arm and the protonated adjacent nitrogen in the cyclen ring. This 
bond is probably weakened in the presence of sodium ions. Since the 
structural changes of the macrocyclic ligands are not so dramatic, it can 
be supposed that the protonation scheme will be valid for other DO3A-like 
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derivatives. The indirect proof is the fact that the overall protonation 
constant log Kp,2  representing the protonation of two nitrogen atoms in the 
cyclen ring are similar: 20.67 (DO3A), 20.40 (DO3AMP), 21.03 (16). The 
overall basicity of the ring nitrogens remains while the change of the 
protonation of the first nitrogen atom is simultaneously compensated by 
the change of the ability of the second nitrogen atom to be protonated 
(Figure 7).  
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Figure 7. Bar diagram of the stepwise dissociation (protonation) 
constants of studied and discussed macrocyclic ligands.  
 
 
The same phenomena can be observed for the overall protonation 
constant, 
 
representing the protonation of two nitrogen atoms in the cyclen 
rim and two acetate pendant arms (Figure 8). Comparing the protonation 
patterns in the bar diagram, the DO3A-like derivatives are more similar to 
DO3A than to DOTA. In addition, the protonation constant of the 
phosphonic acid is dependent on the length of the chain of the pendant 
General Part 
 50 
arm (Figure 9) and is approaching the protonation constant of 
methylphosphonic acid (log Kp = 7.54, I = 0.1 M NaCl, t = 25 °C).141  
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Figure 8. Bar diagram of the overall protonation constant of studied 
and discussed macrocyclic ligands.  
 
 
This effect is probably related to the weakening of the hydrogen bond with 
prolongation of the chain length and thus the phosphonic functional group 
becomes less acidic. This is supported also by the fact that the DO3APP 
ligand has the most compatible pattern of the protonation constants to 
DO3A. It probably means that the propylphosphonate arm does not take 
part in the formation of the hydrogen bond. Also it cannot be excluded that 
the phosphonate group can interact with other acetate arms. In case of the 
protection of the phosphonate pendant arm in the form of bis(esters), the 
lower protonation constants of nitrogen atoms of the cyclen ring were 
determined and they are much closer to the values found for DOTA than 
for the mixed macrocyclic ligands DO3AMP, DO3AEP, 16. This sharp 
decrease of basicity was observed also for other macrocyclic ligands 
having ester groups142,143. 
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Figure 9. Plot of dissociation constant of phosphonic pendant functional 
group bound to macrocyclic ring as function of the number of 
carbon atoms in the pendant arm chain. 
 
 
 
Determination of the stability constants of the calcium(II) 
complexes  
 
 
The interaction of calcium(II) ions with the macrocyclic ligands was studied 
by means of potentiometric titration with a glass ion-selective electrode. 
The results are given in Table 3. As it can be seen (Figures 10 and 11), 
the highest stability of all calcium(II) complexes shows DO3AMP which is 
comparable with that of DOTA. The order of the stability of the calcium 
complexes is as follows: DO3AMP ≈ DOTA > 16 ≈ DO3A > DO3AEP. This 
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can be explained by steric reasons. Interestingly they also decrease with 
the ability of the phosphonate to bind to gadolinium. 
The first protonation constant of the CaL complex is related to the 
protonation of the oxygen atom of the phosphonic pendant arm which is 
not coordinated to the calcium(II) ion (Chart 6). On contrary, protonation 
constant of the second oxygen of the phosphonate does not depend on 
the chain length as it was observed for the first protonation constant. The 
second and third protonation constants belong to the protonation of the  
 
 
 
 
 
 
[Ca(H2L)]- - [H+][Ca(H3L)] - [H+] [Ca(HL)]2- - [H+] [Ca(HL)]2- - [H+]
 
 
Chart 6. Formation of calcium complexes with DO3A based 
phosphonate containing ligands.136 
 
 
nitrogen atoms of the cyclen ring (Chart 6). This hypothesis is supported 
by the fact that the proton affinity increases with the prolongation of the 
chain length of the phosphonic pendant arm. This is a consequence of the 
longer distance between the calcium(II) ion and the macrocyclic ring. In 
addition, the same decrease of the stability constants of the calcium(II) 
complexes in a sodium chloride medium was observed as for the ligand 
protonation which is in agreement with literature data.142,144 The stability of 
the calcium(II) complexes of ligand 18 where the phosphonic group is 
blocked by the ethylester functions is slightly decreased.  
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 Table 3. Logarithmic values of stability constants of complex formation with studied macrocyclic ligands 
Reaction a DO3A DOTA DO3AMP DO3AEP 16 18 
Ca + L CaL 11.96 13.39f) 
(12.16d)) 
17.22f) 
(14.19d)) 
17.38f) 
(13.27d)) 
9.56 11.99 10.13 
Ca + L + H Ca(HL) 17.47 --- --- 24.87f) 
(21.10d)) 
17.18 19.68 14.8e) 
Ca + L + 2H Ca(H2L) 22.82 --- --- 29.05f) 
(25.28d)) 
22.49 25.71 --- 
Ca + L + 3H Ca(H3L) --- --- --- 32.16f) 
(28.39d)) 
27.74 30.97 --- 
CaL + H Ca(HL) 5.51 --- 3.80f) 7.83 7.62 7.69 4.7e) 
Ca(HL) + H Ca(H2L) 5.35 --- 3.77f) 4.18a) 5.31 6.03 --- 
CaL + 2H Ca(H2L) 10.86 11.36f) 7.57f) 12.01 --- --- --- 
Ca(H2L) + H Ca(H3L) --- 3.8f) --- 3.11 5.25 5.26 --- 
Ca + HL Ca(HL) 6.28 --- 9.28 10.75 7.12 8.59 5.41 
Ca + H2L Ca(H2L) 2.15 2.79 3.29 8.39 2.32 4.67 --- 
Ca + H3L Ca(H3L) --- 2.33 --- 7.16 0.86 2.76 --- 
CaL + OH CaL(OH) --- --- --- --- --- --- -11.6 
GdL + H Gd(HL) --- --- --- 5.42 --- 5.2 --- 
GdL(H2O) GdL(OH) + H --- --- --- -12.72 -11.2 -11.4 -11.1 
Ca + GdL Ca(GdL)  --- --- --- --- --- 2.7 --- 
 
a)The charges are omitted for the sake of clarity; b)t = 25 °C, I = 0.1 M NaCl (otherwise the medium is mentioned), c)for logK 
 
the 
standard deviation ≤ 0.04 logK unit (calcium(III) omplexation) or ≤ 0.2 logK unit (gadolinium(III) complexation); d)ref. 136 – corrected for 
sodium ion concentration; e)estimated value; f)ref. 139  
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Figure 10. Bar diagram of the stability constants of calcium(II) 
complexes of studied and discussed macrocyclic ligands.  
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Figure 11. Bar diagram of the stability and dissociation constants of the 
calcium(II) complexes studied. 
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Properties of the gadolinium(III) complexes 
 
 
The stability constants of gadolinium(III) complexes found in literature vary 
for different experimental conditions (mostly pH, kind of inert electrolyte, 
temperature, etc.) and employed experimental techniques137. Probably the 
most critical parameter is the reaction time in acidic pH where the 
complexation reaction is taking place in about several hundreds of hours. 
Therefore there are discrepancies in values of the stability constants 
reported in literature.137 In order to overcome these difficulties, the 
equations based on LFER (linear free energy relationships) for the 
estimation of the stability constant of gadolinium(III) complexes from 
acidobasic properties were derived as: log KGdL = (0.85 ± 0.02) × Σ pKa 
(Table 4).140 Using this equation, the stability constants of gadolinium(III) 
complexes were estimated to: 24.0 (GdDO3A), 25.0 (GdDOTA), 29.2 
(GdDO3AMP), 29.8 (16), 22.0 (18) (Table 4).  
 
Table 4. Calculated stability constants of gadolinium complexes 
Compounds 
 
logKGdLa) logKGdLb) logKGdLc) 
GdDO3A 24.0 19.2 21.2(20.00) 
GdDOTA 25.0 22.4 26.6(23.6) 
GdDO3AMP 29.2 21.1 26.8(23.0) 
17a 29.8 19.3 --- 
19a 22.0 16.7 --- 
    
 
a)
 log KGdL = (0.85 ± 0.02) × Σ pKa; 
b)
 log KGdL = (1.4 ± 0.1) × log KCaL + (2.5 ± 1.2); (calculated 
for NaCl medium)  
c)
 values corrected for a sodium chloride medium (calculated 
for TMACl medium).;  
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The complexing properties with respect to calcium(II) ion can be used as 
well to calculate the stability constants: log KGdL = (1.4 ± 0.1) × log KCaL + 
(2.5 ± 1.2). This relationship suggests that any differences in the stability 
of both complexes are the same. Applying the above mentioned 
relationships simultaneously with the knowledge of the stability constants 
of the calcium(II) complexes the following stability constant of Gd(III) 
complexes were calculated: 19.2 (GdDO3A), 22.4 (GdDOTA), 21.1 
(GdDO3AMP), 19.3 (17a), 16.7 (19a) (Table 4). The logarithmic value of 
the stability constant for the GdL complex corrected for a sodium chloride 
medium is 23.7 (GdDO3AMP), 19.8 (GdDO3A), 20.6 (GdDOTA) (Table 4). 
This was used to verify the calculations. As it can be seen, the 
experimentally obtained values are in the range of limits found for both 
estimations but they are closer to the values obtained from CaL-GdL 
according to LFER. The overestimation obtained from the overall 
protonation constant can be caused by the fact that all pendant arms are 
considered as potential binding sites which cannot be a real situation in 
case of the longer phosphonic arm of 17a. However, the solved solid-state 
structure and NMR study of Ln(III) complexes of DO3AMP ligand proved 
that the lanthanide(III) ions are fully bound by this octadentate ligand.145,146 
The calcium(II) ion can be bound by the gadolinium(III) complex and a 
rough estimate of the stability constant of the ternary complex [Ca]17a is 
about 2.7 (Table 3). This value is higher than that described for the 
stability constant of the calcium(II) complex with methylphosphonic acid 
(DOA3MP) (log K ≈ 1.6). This could be either a consequence of Ca(II) 
binding not only to the phosphonate group but also partially to the acetate 
arms which contribute to stabilize the chelate. On the other hand in 17a 
the phosphonate group provides two hydroxyl functions to bind calcium. 
All the known values of the equilibrium constants were used to simulate 
the distribution diagrams of the gadolinium(III) complex as function of 
solution acidity (Figure 12). The results are in agreement with those 
obtained from pH dependence of the relaxivity of the GdL complexes. 
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Figure 12. Distribution diagram of the protonated species of complex 
17a. 
 
Thus complex 17a is suitable for relaxiometric measurements at pH 
between 4 and 7 while 17a slowly decomposes at pH < 3. Complex 17a is 
capable of binding calcium(II) in mM concentrations in the physiological 
region at pH = 7.4 (Figure 13). Therefore 17a can be considered as a 
promising diagnostic agent for the study of neurochemical processes. 
 
Figure 13.  Distribution diagram of calcium(II) ion binding by gadolinium(III) 
complex 17a (pH 7.4). 
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Relaxivity studies of the complexes 17a and 19a 
 
 
The paramagnetic properties of the gadolinium(III) complexes 17a and 
19a have been studied by relaxometry at low magnetic fields (20 and 60 
MHz, 37 °C, Figure 14) as well as at high magnetic field (300 MHz). The 
most dramatic change of the relaxivity for both complexes is observed in 
the pH range between 4 and 7. The relaxivity (20 MHz) of 4.79 mM-1s-1 
(17a) and 3.83 mM-1s-1 (19a) at neutral pH increase upon acidifying the 
solution medium to pH 4 up to 5.90 mM-1s-1 (17a) and 8.57 mM-1s-1 (19a), 
respectively. This is equal to 23% of relaxivity changes for compound 17a 
and 60% for 19a. Experimental values determined for the same samples 
and under similar conditions (pH, temperature) at 60 MHz were similar to 
those at 20 MHz.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Relaxivity vs. pH for the unprotected (17a) and protected 
(19a) phosphonates (20 MHz, 37 °C). 
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The decrease of the relaxivity at higher pH can be explained either by the 
formation of ternary complexes with carbonates from the CO2 from air or 
by the exchange of water molecules with the OH groups in basic 
conditions. The pH dependence of the relaxivity at low pH could be due to 
the presence of uncoordinated phosphonate groups in the complexes 17a 
and 19a. The protonation of these groups can catalyze the exchange of 
protons between the bound water molecule and the bulk water by 
providing an efficient hydrogen bond network.151 To demonstrate that pH 
changes can be sensed in MR imaging experiments, two phantoms each 
consisting of four Eppendorf tubes, filled with 2 mM solutions of CA at 
different pH (4, 5, 6 and 7) were prepared and T1-weighted images were 
obtained (Figure 15). The results demonstrate a relative increase of 46% 
for 17a and 37% for 19a in the relaxation rate between pH 4 and 7, giving 
a promising outlook for the application of compounds 17a and 19a as CAs 
even in high field MRI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Phantom images of 19a and 17a in the pH range 4-7 (top) 
and the appropriate fractional increase of T1 (bottom). 
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31P NMR spectra of the europium complexes were recorded to prove, that 
no dissociation processes take place at low pH (Figure 16). As it is shown, 
no changes in the spectra are observed by allowing the sample to stay for 
several days in solutions with pH 4 to 10. Slow decomplexation was 
observed in the spectra after one day at pH 3, which is shown as an 
additional signal in spectrum c. The lifetime of the complexes at pH below 
2 was found to be around 30 min.  
 
a
b
c
d
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0 -404080 -80
 
 
Figure 16. 31P NMR spectra of the Eu DO3APPE (19b) complex versus 
pH: a) pH 7, b) pH 4, c) pH 3 and d) pH 2; (H3PO4 used as 
reference 0 ppm). 
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This was confirmed by the potentiometric studies of the complexes. 
According to these results it can be concluded, that the change of the 
relaxivity in the pH range between 4 and 7 is not due to decomplexation 
processes and release of the free gadolinium ions into the solution. 
The relaxivity behavior of complexes 17a and 19a at different 
temperatures were studied at 20 MHz (Figure 17). The water proton 
relaxivities of the compounds increase when the temperature is lowered 
from 40 to 5 °C independent of the pH, which indica tes that at low 
temperatures there are no limitations by the water residence time.  
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Figure 17. Evolution of the proton relaxivity vs. temperature for the 
compounds 17a and 19a at pH 4 and 6. 
 
 
The interpretation of the evolution of the relaxivity as a function of 
magnetic field in the NMRD profiles (Nuclear Magnetic Relaxation 
Dispersion profiles), with the help of appropriate theoretical models allows 
to get information about the parameters governing the relaxivity (like 
τM,  τR, τSO, τv ….)(Table 5).151 The experimental data were fitted using 
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either the classical innersphere (IS) and outerspehre (OS) model or 
innersphere (IS), outerspehre (OS) and second sphere (SS) model (Figure 
18).  
 
Table 5.  Fixed and found data of NMRD profiles fitting 
 
Compound 
 
19a pH 6 19a pH 4 19a PH 4 17a pH 6 17a pH 4 17a pH 4 
model IS+OS IS+OS IS+OS+SS IS+OS IS+OS IS+OS+SS 
d (nm) 0.36 0.36 0.4 0.36 0.36 0.4 
D 
(10-9 m2s-1) 
3.3 3.3 3.3 3.3 3.3 3.3 
r (nm) 0.31 0.31 0.31 0.31 0.31 0.31 
τR (ps) 76 92 75 51 64 51 
τM (ns) 100 100 100 100 100 100 
τSO (ps) 74 159 95 69 77 51 
τV (ps) 24 40 24 7 13 7 
q 2 2 2 2 2 2 
rss(nm)   0.36   0.36 
qss   4   3 
τSS (ps)   30   30 
 
 
The following parameters were fixed: 
IS + OS model: distance of closest approach d = 0.36 nm, relative 
diffusion constant D = 3.3 10-9 m2s-1, distance for the innersphere 
interaction (r) = 0.31 nm, number of coordinated water molecules (q) fixed 
to 1 or 2 depending on the complex, the water residence time (τM) to a 
value which does not influence the fitting (100 ns). 
IS + OS + SS model: distance of closest approach d = 0.4 nm, relative 
diffusion constant D = 3.3 10-9 m2s-1, distance for the innersphere 
interaction r = 0.31 nm, number of coordinated water molecules (q) fixed to 
1 or 2 depending on the complex, the water residence time (τM) to a value 
which does influence the fitting (100 ns).  
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The rotational correlation time (τR), the electronic relaxation time at zero 
field (τSO), the correlation time responsible of the modulation of the 
electronic relaxation (τV) were adjusted in both models. In addition, when 
the second sphere model is included, the number of second sphere water 
molecules (qss), and the correlation time for the second sphere model 
(τSS= [τR-1 +τMss-1]-1) are adjusted whereas the distance for the second 
sphere was set to 0.36 nm (Table 5).  
 
 
 
 
 
 
 
 
Figure 18. NMRD profiles of the complexes 17a (left) and 19a (right) 
Figure 18.  NMRD profiles of the compounds 17a and 19a. 
 
 
For both complexes, at pH 6, the IS+OS fitting is well. At pH 4, better 
results are obtained with the IS+OS+SS model for the compound 19a but 
for complex 17a both models fit correctly the data.  
Nevertheless, it is to be noticed that at pH 4 when only IS + OS is used, 
the value of τR has to be increased or the value of q has to enhance 
whereas when the SS is included τR is similar at both pH. That, probably 
means, that at low pH secondary sphere water molecules form which 
contribute to the relaxivity increase considerably.
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2.2.4. Conclusions 
 
 
In conclusions, the synthesis and initial physicochemical studies of two 
novel contrast agents has been achieved. They are designed to exhibit 
relaxivity changes in different pH environments, since the pH sensitive, 
phosphonate group is appended to the macrocyclic ring. Comparison of 
the acidobasic properties of the ligands (16 and 18) and complexes (17 
and 19) with the literature data shows that pKa of the phosphonates 
depend on the length of the side chain and the phosphonates do not 
contribute to the thermodynamic stability of the gadolinium and calcium 
complexes. Relaxometric experiments with complexes 17a and 19a have 
been performed at various magnetic fields (20, 60 and 300 MHz) and pH 
of solutions (pH 4-10). The most interesting results were obtained at acidic 
pH where relaxivity of 17a and 19a increased by 23% and 60% 
respectively, when the pH of the medium has changed from neutral to pH 
4 (20 MHz). The phantom images at 300 MHz confirm the possibility to 
sense the contrast changes visually. 31P NMR spectra of the europium 
complexes were recorded to prove, that no dissociation processes take 
place at low pH. The complexes are stable in the range of pH 4 to 10, but 
slow decomplexation was observed in the spectra after one day at pH 3. 
The lifetime of the complexes at pH below 2 was found to bee around 30 
min. This was confirmed by the potentiometric studies of the complexes. 
According to these results it can be concluded, that the change of the 
relaxivity in the pH range between 4 and 7 is not due to decomplexation 
processes and release of the free gadolinium ions into the solution. 
The potential application of reported complexes with the relaxivity changes 
in the range of pH 4-7 might be found in the diagnosis of e.g. late stages 
of cancer, or the detection of the necrotic core of cancer tissues, where 
very low pH values could be observed. With the further optimizations of 
compounds which should show larger relaxivity changes in the relative 
small physiological pH range, one could find much broader applications. 
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Such contrast agents might be used not only in early cancer diagnostic but 
also as functional markers in the tracking of regular physiological pH-
dependent processes in vivo. 
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2.3. Synthesis and characterization of DO3A based 
amino(bismethylene)phosphonate complexes as 
potential Ca sensitive contrast agents 
 
2.3.1. Introduction 
 
 
Aminophosphonic acids are becoming increasingly important for biological 
applications152-154 as well as in the design of new synthetic ligands as 
chelating agents for metal ions.155-159 This fact provides new evidence for 
the effectiveness of aminophosphonate donor groups in the binding of 
metal ions, and provides more precise data for the phosphonate analogue 
of DTPA and EDTA (Cart 15a and c).160-161 Over the last years series of 
CAs for MRI with aminophosphonates and bis(phosphonates) as targeting 
group have been developed162-164  Aminophosphonates are known to have 
affinity for calcified tissue and a series of EDTA and DO3A based 
compounds were investigated as potential bone targeted contrast agents 
for MRI (Chart 15b and d).165   
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Chart 7. Aminophosphonates as chelators for gadolinium. 
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The properties of amino polyphosphonates (APP) were reported by 
Schwarzenbach and physico-chemical characteristics studied by Martell in 
comparison with amino polycarboxylates (APC).166-171 
The thermodynamic characteristics and complex affinity of 
aminophosphonates towards the alkali and alkali-earth elements was 
described in a series of publications.172-176 It was shown that the stepwise 
replacement of N-acetate by N-methylenephosphonate groups in 
nitrilotriacetic acid (NTA) results in an increase in the Ca2+ and Mg2+ 
stability constants, although the increase over NTA does not follow a linear 
relationship. There is no large decrease in binding of Ca2+ and Mg2+ in 
going from nitrilotrimethyltriphosphonates (NTMTP) to its N-oxide. This 
suggests that binding of Ca2+ and Mg2+ in compounds containing the 
NCH2P03H2- moiety is principally by the phosphonate group with little or 
no interaction by the tertiary nitrogen (Chart 8). The formation constant of 
magnesium chelates with amino polycarboxylate is usually smaller than 
that of calcium and the same behavior is expected for the similar 
aminophosphonates.177 
 
 
 
 
 
 
 
Chart 8. Complex formation of amino(bismethylene)phosphonates 
with the alkali-earth metals. 
 
The hydration energy of Mg2+ is fairly large because of its small ion size, 
and thus the enthalpy of the formation of Mg2+ chelates is much smaller 
than those of other alkaline earth-metal ions.178 
Among the several factors the steric crowding effect was discribed to be 
the important issue to influence the rate at which the gadolinium bound 
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water exchanges with molecules into the bulk.179,180 Furthermore the 
overall charge of the chelate ligand has an impact of water exchange rates 
and thus of altering the relaxivities of the complexes.181 Negatively 
charged substituents on the surface of paramagnetic complexes are able 
to bind water molecules which contribute to the overall relaxivity of the 
complexes.182,183   
According to these data the DO3A based macrocyclic compounds with the 
variable length of the methylenphosphonate side chain was designed 
(Chart 9). Due to the higher affinity of Ca2+ towards AMP it is expected that 
Ca2+ ions can bind to the phosphonate groups leading to a reduced overall 
charge of the complexes and/or generate an additional coordination side 
at the gadolinium. Both effects should provoke the water exchange rates 
and thus result in a change in relaxivity. In this way the complexes act as 
Ca2+ sensitive contrast agents. The different lengths of the 
(aminobis)methylenephosphonate side chains allow exploiting the fine-
tuning of the sensitivity of the agent towards calcium ion concentration. 
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Chart 9. Macrocyclic compounds with variable length of the side chain 
                     25a, n = 1; 25b, n = 3: 25c, n = 4.
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2.3.2. Synthesis of the ligands and complexes 
 
The ligands 25a - c were synthesized according to the Scheme 8. 
Aminoalkyl alcohols were brominated with HBr/acetic acid solution and 
amino groups were protected using Boc2O at basic conditions to give 
compounds 21a - c.  
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Scheme 8: Synthesis of the macrocyclic compounds 24a – c, 26a – c, 
27a – c;.a: n = 1; b: n = 3; c: n = 4; i) Boc2O, NaOH, DCM; ii) 
K2CO3, CH3CN; iii) DCM, TFA; iv) H2O, GdCl3 x H2O (24a – 
c); v) H3PO3,H2CO, H2O;vi) H2O, GdCl3 x H2O (26a – c), 
H2O, EuCl3 x 6H2O (27a – c). 
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The tert-butyl ester of DO3A185(14) was alkylated with the corresponding 
Boc protected bromoalkylamines to give 22a – c. The carboxyl and amino 
groups were deprotected in a one step reaction with trifluoroacetic acid in 
dichloromethane. After recrystallisation from diethyl ether followed by 
recrystallization with acetone the aminoalkyl substituted DO3A 23a – c 
were obtained. Remowing of the TFA was followed by 13C NMR 
spectroscopy. The methylenephosphonates were attached to the amino 
side chains by a Mannich reaction using phosphorous acid and 
formaldehyde at 100oC.186 After recristallization from water / ethanol or 
water / isopropanol solutions finally the ligands 25a – c were obtained as a 
colorless powders. Several times recrystallization were requiered to 
remove the excess of phosphoric acid which was followed on 31P NMR 
spectroscopy. The synthesized ligands were characterised by 1H, 13C, 31P 
NMR spectroscopy and HR-MS spectrometry. Characteristic resonances 
are presented in the13C NMR spectrum of compounds 26c (Figure 19). 
Due to the interaction of the carbon 14 with the phosphorous nucleus the 
resonance is split into a doublet (1JPC = 33.8 Hz). 
 
 
Figure 19.  13C{1H} NMR spectrum of compound 26c.  
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Stock solutions of the metals with known concentrations were prepared 
from the chloride salts of the corresponding metals. The exact 
concentrations were determined by the complexometric titration with the 
standard solution of the disodium salt of EDTA. The complexes 26a – c 
and 27a – c were formed by stirring the mixtures of the corresponding 
stock solutions and ligands in a ligand : metal ratio 1 : 0.9. Finally the 
complexes were filtered and lyophilized. The xylenol test was preformed to 
insure that there are no free metal ions in solution. The formations of the 
complexes were confirmed by the ESI-MS mass spectrometry in the 
negative and positive mode. The molecular ion peaks with the 
characteristic seven isotopes for the gadolinium(III) complexes 26a – c 
were present in the spectra. In the mass spectra of compounds 27a – c all 
peaks related to the mass of the [M+H]+, [M+Na]+ and [M+2Na]+complexes 
are observed.  
 
 
2.3.3. Physico-chemical characteristics of the ligands and 
complexes 
 
 
Potentiometric studies of the ligands  
 
 
The acidobasic properties of the synthesized ligands 26a – c were studied 
by means of glass electrode potentiometric titrations at 25 °C and  
0.1 M ionic strength (NaCl). Compounds 26a – c represent a set, in which 
each of the phosphonate (PO32-) groups is capable of accepting two 
protons and the nitrogen atom of the aminophosphonates moiety one 
proton. Fully protonated ligands contain ten dissociable protons [H10L]. 
However, under the applied experimental conditions only seven 
deprotonation processes could be detected (Scheme 9). The reason for 
this is the strong acidity of PO3H2 groups, which prevents evaluating the 
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first two pK values from the pH-metric titration in water. On the other hand, 
the strong basicity of the nitrogen protons of the aminophosphonate 
moieties causes the last pK value undetectable as it is too high. The 
exceptionally high basicity of the nitrogen protons can be explained by the 
formation of intermolecular hydrogen bonds between the oxygen of the 
phosphonate groups and hydrogen of the protonated iminogroups.187 
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Scheme 9. Protonation of the compounds 26a – c (only the steps where 
the protonation constants could be determined are shown). 
 
General Part 
 73 
The pK values characteristic for the dissociation of the two protons from 
the two –PO3H2 groups are ~ 1 – 1.5 and thus they are fully deprotonated 
in the pH range studied and do not take part in metal coordination 
equilibria. Further deprotonation of the phosphonic groups may cause an 
overlapping of the pK values, which means that the pK values of –PO3H- 
are not characteristic for the real acidity of this groups.188-189 The basicity 
of the compounds increase with the increase of the length of the 
phosphonate side arm (Table 5 and Figure 20).  
 
 
Table 5. The protonation constants of the ligands 26a – c (t = 25 °C,   
I = 0.1 M NaCl) 
Ligand logKp,1 logKp,2 logKp,3 logKp,4 logKp,5 logKp,6 logKp,7 
26a 9.61 9.30 6.03 5.01 3.51 1.7a) 1.7a) 
26b 10.14 9.41 6.08 4.82 4.34 --- 3.49a) 
26c 10.16 10.13 7.12 6.32 5.39 4.32 3.71a) 
 
a)Estimated values 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. The bar diagram of the stepwise dissociation (protonation) 
constants of studied and discussed macrocyclic ligands.  
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That can be explained by weaknesses of the interactions between the 
cyclen rim and the phosphonate containing side arm. Also it cannot be 
excluded that the phosphonate groups can interact with other acetate 
arms or forming dimeric units consisting of hydrogen bonds due to the 
PO3H2 / PO3H- interaction between the side arms of two molecules. That 
will lead to higher protonation constants. This can be seen from the 
diagram of the overall protonation constants (Figure 21) representing the 
protonation of two nitrogen atoms in cyclen rim and two acetate pendant 
arms. The basicity of the ligands 26a – c increases by prolongation of the 
side chain. Probably, the prolongation of the side chain facilitates the 
formation of dimeric units. 
DO3A DOTA 26a 26b 26c
20
25
30
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g ββ ββ
p
ΣpK (2N + 2 COOH)
 
 
 
Figure 21. Bar diagram of the overall protonation constant of 
macrocyclic ligands. 
 
Relaxivity measurments 
 
 
The paramagnetic properties of Gd complexes 26a – c were studied by 
relaxometry at high magnetic fields (300 MHz, 21°C)  (Figure 22(left)) The 
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T1 relaxation time of water was measured for four concentrations of the 
complexes 26a – c (0.1, 0.4, 0.7 and 1.0 mM) while varying the 
concentrations of Ca2+ ions from 0 to 100 mM. Relaxivity was calculated 
as the slope of the graph of the linear dependence of relaxation rate 1/T1 
vs concentration of the complexes. No significant changes of the water 
relaxivity of 26a were found over the whole span of Ca2+ concentration. 
Interestingly, the water relaxivity of 26b solutions which remained constant 
in Ca2+ concentrations from 0 to 1.0 mM dropped from 3.49 to 2.56mM-1s-1 
when the Ca2+ concentration was increased to 10 mM. More importantly in 
26c solutions the major effect of the change in relaxivity was shifted to the 
Ca2+ concentration range from 0.01 to 5 mM which is covering the 
physiologically relevant area (0.5 – 2.5 mM for extracellular conditions). A 
maximum decrease in r1 of 36% and of 11% within the physiological range 
was observed (Figure 22(right)).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Relaxivity studies of complexes 26a – c (left) and relaxivity 
                     rate vs calcium concentration in physiological range for 
                     compound 26c. 
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To confirm that the changes of relaxivity are because of changes in 
calcium concentrations, an experiment in the presence of EDTA as a 
strong calcium chelator was performed. In each Ependorf tube which was 
used in the experiment with calcium (Figure 22 (left)) 1 eq. of EDTA was 
added. After complexation with EDTA no calcium should be in solution and 
relaxivity will be the same for all probes. As expected (Figure 23), after all 
calcium was taken by EDTA no relaxivity changes were observed any 
more between the samples. This confirms, that the changes in relaxivity in 
the first experiments were due to calcium. Furthermore the changes of 
relaxivity are reversible. 
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Figure 23. Relaxivity vs calcium ions concentration measurments in 
                     presence of equimolar concentratons of EDTA for compound  
                     26a. 
 
 
 
In order to simulate in vivo conditions where a number of other ions 
compete with Ca2+, relaxivity studies were performed in artificial 
cerebrospinal fluids (ACSF)190. Still the relaxivity decreased by 30% in 
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CSF, which implies that compound 26c is a potential candidate to act as a 
CA for the detection of modulations of extracellular Ca2+ concentrations. 
The next experiment was designed to study the behavior of compound 
26c in the presence of a protein mixture. Therefore the experiments were 
repeated in the presence of streptochinase proteins mixture at 37oC and 
results were compared with those in the protein free solutions. The results 
are presented on the Figure 24 according to which the longitudional 
relaxation time is by the variation of calcium ion concentrations also in the 
presence of proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Relaxation rates vs calcium concentrations in the presence 
                     and absence of protein mixture. 
 
 
The relaxivity versus temperature were measured at 20 MHz (Figure 25). 
Decreases in relaxivity were observed for all measured compounds in the 
range of 5°C to 45°C. These results indicate that a t low temperatures 
there are no limitations by the water residence time. 
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Figure 25. Relaxivity vs Temperature in the absence and presence of 2  
mM Ca2+. 
 
 
31P NMR studies of europium complexes 
 
 
In the 31P{1H} NMR spectra of 27a – c up to four signals are observed 
(Figure 26). They originate from the different coordination isomers which 
behave like diastereotopomers. The differences of the 31P chemical shifts 
of the 27b and 27c complexes compared to their free ligands are rather 
small. This indicates that the phophonate groups are not coordinated to 
europium, while the chemical shift difference of 20 ppm in the case of 27a 
points to an interaction between the metal center and the phosphonate 
functions.181-183 Interestingly the 31P resonances of 27a are not affected by 
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the addition of Ca2+ ions to solutions of 27a whereas the linewidths 
increased dramatically when the Ca2+ concentration is increased in the 
solutions of 27b and 27c, respectively. These results are in line with the 
relaxivity studies of the corresponding gadolinium complexes. Moreover 
after a addition of 2.5 eq of calcium to a solution of 27c the hight field 
resonances are relaxed to the base line. This indicates the different 
diastereotopomers have a different inpact on the relaxivity. 
 
 
 
 
 
 
 
 
 
 
Figure 26. 31P{1H} NMR spectra of compounds 27a (left) and 27c (right) 
at 400 MHz, 0oC a) without calcium, b) 0.5 eq of calcium, c) 
2.5 eq of calcium. 
 
On the other hand in the amino(bismetylenephosphonate) side chains the 
two phosphonates provide negative charges. In conjunction with the 
appropriate length of the side chain this leads to the formation of the 
second sphere water of the gadolinium complexes which enforce the 
overall relaxivity of 26c by endorsement of the water exchange rate184. As 
the Ca2+ cations neutralize the negative charge of the phosphonates, the 
water exchange rate is reduced which results in a decrease of the 
relaxivity. 
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2.3.4. In vivo studies 
 
 
In vivo experiments in rats have been performed to characterize the 
distribution, half - live time and toxicity of the new contrast agent 26c in the 
extracellular space of the brain. The feedback information that can be 
obtained from these experiments is essential to optimize the agents for in 
vivo situations adapting the chemical synthesis and MR contrast agent 
design/behavior. 
The knowledge of the diffusion properties of the injected compounds in the 
in vivo experiments provides the information about their distribution in the 
tissue. The ideal compound should diffuse well from the ventricles and 
distribute all over the brain enhancing the overall contrast of the tissue. 
During the stimulations increase or decrease of the signal should be 
observed in the area of the brain responding to stimulation. Therefore, the 
first experiments of the direct injections into the ventricles have been 
performed in order to study the diffusion properties of complex 26c (Figure 
27).  
 
 
 
 
 
 
 
 a                           b                             c                                 d 
 
Figure 27. Injection of the compound 26c into the cerebroventricles. Pre 
injection (a), after 6 min (b), after 26 min (c) and after 1h (d). 
 
The animals were prepared as described in the literature.191 Injections 
were performed on animals which were placed inside the magnet in order 
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to provide a whole picture of the distribution of the contrast agent. The 
injections were done through a 4 m long sharpened fused silica capillary. 
250 nL of the 20 mM solution of compound 26c in ACSF (pH 7.4) was 
injected slowly over a period of 20 to 40 min. An increase of the contrast in 
the ventricular area directly after injection was observed (Figure 27b). 
 Unfortunately the compound was washed out without the visible diffusion 
in the brain tissue. After 26 min of injection the signal was reduced (Figure 
27c) and almost no contrast was detected after 1h (Figure 27d). 
The second series of the experiments were performed to study the 
diffusion of the compound in the brain by direct injection into the tissue. In 
these experiments injection was performed using the same method as it 
was described before. 120 nL of 20 mM solutions of 26c in ACSF was 
slowly injected into the brain tissue of the animals. The results of the 
injection are presented in the Figure 28 and diagrams of the compound 
distribution in the tissue are shown in the Figure 29.  
 
 
          a                              b                              c                              d 
 
Figure 28. Direct injection of the compound 26c into the brain tissue. 
a) reference; b) direct after injection; c) 1h after injection; 
d) 2h after injection.  
 
Injection of the compound 26c into the tissue, results in a local decrease 
of T1 values which can be seen as a white spot on the image (Figure 28b). 
The dark point inside the spot (Figure 28b), related to the injection place 
where the concentration of the contrast agent 26c is very high. This 
dramatically reduced the T1 relaxation time of the tissue and as a result 
the signal can not be detected. Moreover some amount of the compound 
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diffused into the ventricles and this results in the additional white spots in 
the Figure 28b. After 20 to 30 min the white spot becomes bigger (Figure 
28c), but no further visible changes for the time of the whole experiment (~ 
5 – 6h) were observed (Figure 28d). The diffusion of the compound can be 
followed by the distribution diagrams (Figure 29) according to the time 
course (top) and comparison of the signal intensity vs. the distance from 
the injection point (bottom). 
 
 
 
Figure 29. Diffusion diagrams of the injected compound 26c in tissue 
(different colors are the MR signal intensity related to the 
brain tissue without the contrast agent). 
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According to the diagram there is a very small diffusion and slow washout 
of compound during the whole time of the experiment. The maximal signal 
intensity is observed in the place of injection and it is almost constant in 
the time course. That can be a cause of the interaction of the negatively 
charged phosphonates with the cell membranes or with the proteins in the 
extracellular space. 
The next step for in vivo experiments was performed in order to study the 
neuronal toxicity of the new compounds. Neuronal toxicity of the 
synthesized complex 26c has been investigated by means of combined 
electrophysiological and fMRI experiments. Electrophysiological 
recordings and fMRI (BOLD) experiments were performed in Long Evans 
rats upon visual stimulations (1 and 4 Hz flickering), before and after the 
injection of the contrast agent 26c into the visual cortex. After the local 
injection of 40nL of 20mM solution of compound 26c in ACSF the tissue 
was allowed to recover for 15-20 min before the stimulation and recording 
was repeated. The recorded data were compared and results for the fMRI 
experiments are shown on the Figure 30. 
 
 
 
 
Figure 30. Electrophysiological recording (left) and BOLD images (right) 
of post injection of the compound 26c. 
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The fMRI experiment shows the normal neuronal activity after injection of 
compound 26c (Figure 30, right). The same results were obtained from the 
electrophysiological data analysis (Figure 30, left), which shows the 
normal firing of the neurons after the injection. Moreover the complex is 
not toxic for the neurons and can be used for further in vivo studies. 
The most important series of the in vivo MRI experiments were performed 
to investigate contrast changes due to neural activations. For that purpose 
standard sensory stimuli (visual and somatosensory) were used. The 
injections were performed outside of the magnet. The compound 26c 
(40nL of 20mM in ACSF) was injected in the right side of the visual or 
somatosensory cortex of the rat, while the left side was used as a control. 
Either visual (1 and 4 Hz flickering), whisker stimulations (air puffs) and 
hindpaw electrical stimulations were performed inside the magnet and T1-
weighted scans were acquired. Terminal depolarization was performed at 
the end of the each experiment to get a possible biggest change of the 
extracellular calcium concentrations in vivo. The analysis of the above 
experiments showed no changes in T1 upon applied stimuli.  
 
 
2.3.5. Conclusions 
 
 
In conclusion, a series of lanthanide chelate complexes 26a – c and 27a – 
c with the variable length of the amino(bismethylen)phosphonate side 
chain have been synthetized and investigated. The dependence of the 
length of the side chain on the relaxivity and complexing properties of the 
complexes studied by the means of the potentiometric titration, NMR 
spectroscopy and relaxometry. According to the data of potentiometric 
titration the basisity of the ligands increased with increase of the length of 
the side chain, which can be explained by the interaction of the 
phosphonate moieties with the nitrogen atoms of the cyclen rim. T1 
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relaxivity changes in the presence and absence of different concentrations 
of Ca2+ were observed for the complexes 25b and c. For the compound 
26c these changes were observed for Ca2+ concentrations within 
physiological conditions in the extracellular space. To simulate in vivo 
conditions relaxivity measuerments were preformed in artificial CSF and in 
the presence of the mixture of proteins. The changes of the relaxivity were 
observed in both series of experiments. 31P{1H} NMR studies of the 
complexes 27a – c pointed to the presence of diastereotopomers which 
have a different impact on the relaxivity. According to these results, 26c 
has potential to act as calcium dependent MRI contrast agents and it was 
studied under in vivo conditions. In vivo injections in the rats show that the 
complex 26c is not toxic for the neurons, but unfortunately it is not 
diffusing properly while injected in the tissue. Injections in the visual and 
somatosensory cortex of the rats did not show any changes of signal 
during the stimulation. This means that the compound does not works as 
‘smart’ contrast agent in vivo conditions. It can be concluded, that the 
changes of the relaxivity obtained in vitro conditions, probably, are not 
strong enough to observe the signal changes in vivo and further 
modifications of complexes are needed to achieve a detectable changes in 
contrast during the neuronal activity. 
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3. EXPERIMENTAL PART 
 
 
3.1.1. General remarks, material and instrumentation 
 
 
All chemicals were purchased from commercial sources and were used 
without further purification. All dried solvents were stored under argon and 
distilled prior use. 
The lanthanide metal ion solutions with the known concentrations were 
prepared by dissolving an accurately weighted amount of the chloride salt 
in the appropriate volume of doubly distilled water, and standardized with 
the complexometric titration with the disodium salt of EDTA.192 
 
 
NMR 
1H NMR, 13C{1H} NMR and 31P{1H} NMR spectra were recorded on  
BRUKER DRX 250 MHz and DRX 400 MHz spectrometers at room 
temperature and the following frequencies: 1H NMR: 250.13 MHz and 
400.13 MHz respectively. The signals were referenced to the residual 
proton signals of the solvents relative to TMS. 13C{1H} NMR: 62.9 MHz. 
The signals were referenced to the 13C signals of the deuterated solvents 
relative to TMS. 31P{1H} NMR: 101.26 MHz. The signals were referenced 
to external 85% H3PO4. 
 
 
T1 and T2 measurements 
Longitudinal and transverse relaxation times were measured on a Bruker 
Minispec pc120 and mq60 at 20 MHz (0.47 T) and 60 MHz (1.41 T) 
respectively. The concentration of each sample was determined by I.C.P. 
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(Jobin Yvon JY70, Lonjumeau, France) or at 300 MHz on a vertical 7 T/60 
cm MRI Biospec system (Bruker Biospin, Germany). Up to 16 tubes could 
be measured simultaneously. The relaxation rate measurements of the 
samples were performed at room temperature (21 °C).  For R1, a spin-
echo saturation recovery sequence was used, varying the repetition time 
TR and keeping the echo time TE minimal and constant. Typical 
parameters were: field of view 17 _ 6.9 cm2, matrix 512 _ 256, slice 
thickness 4 mm, SW 70 kHz, TE 15 ms, TR 40-8000 ms (logarithmic time 
steps, 80 images). For R2, a multi-spin-echo sequence was used with a 
long TR between excitations. Similar parameters were used, but TR ) 8 s 
and TE ) 17-850 ms (linear echo time steps, 50 echoes). Proton nuclear 
magnetic relaxation dispersion (NMRD) profiles were recorded on a Field 
Cycling Relaxometer (Stelar, Mede, Italy).  The accessible magnetic field 
range is 0.24 mT to 1.2 T, what corresponds to proton Larmor frequencies 
0.01MHz to 20 MHz.  Measurements are done on samples of 0.6 ml in 10 
mm OD tubes. 
 
 
Mass spectra  
FAB spectra were recorded on a Finnigan MAT 711 A modified by AMD 
Company (10 kV, 323K), ESI spectra on an Agilent series 1100 MSD.  
ESI-LRMS (in positive and negative ion mode) were performed on ion trap 
SL 1100 system (Agilent, Germany) and ESI-HRMS were performed on 
Bruker Daltonics Apex II FT-ICR-MS (Bruker,Germany). 
 
 
Elemental analyses  
Elemental analyses were obtained on a Vario EL made by Elemental 
Company. 
 
 
 
Experimental Part 
 88  
Column Chromatography  
Column chromatography was performed on silica gel 60 (70-230 mesh 
ASTM). 
 
 
Reversed Phase High-Performance Liquid Chromatography (HPLC) 
HPLC was performed at room temperature on a Varian PrepStar 
Instrument, Australia, equipped with PrepStar SD-1 pump heads. UV 
absorbance was measured using a ProStar 335 photodiode array detector 
at 214 and 254 nm. This detector is equipped with a dual-path length flow 
cell which enables measurement of absorption of analytical and 
preparative samples without changing the flow cell. Reversed-phase 
analytical HPLC was performed in a stainless steel Chromsep (length 250 
mm, internal diameter 4.6 mm, outside diameter 3/8 in. and particle size 8 
ím) C18 column and preparative HPLC was performed in a stainless steel 
Chromsep (length 250 mm, internal diameter 41.4 mm, outside diameter 2 
in. and particle size 8ím) C18 column (Varian, Advanced Chromatographic 
Solutions). 
 
 
The pH-metric measurements  
The pH metric titrations used in the determination of protonation and 
complexation constants were carried out on the Basic Titrino 794 from 
Metrom (Switzerland) with the combined glass electrode in a 
thermoregulated cell (25.0 ± 0.1 °C) with a nitroge n stream flowing over 
the solution to avoid the dissolution of carbon dioxide. The measured 
experimental data were transferred via RS 232C data interface into 
computer using Metrodata VESUV PC software and then the experimental 
data were treated by OPIUM software190 in order to determine the 
equilibrium constants from titration curves. The combined electrode was 
calibrated using the following calibration function: 
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E = E0 + S log [H+] 
 
where E0 is standard potential including mostly the contribution of 
reference electrode and S corresponds to the Nernstian slope, the value of 
which should be close to the theoretical one. The calibration parameters 
were estimated from titration of diluted solution of standard HCl with 
standard 0.1-M NaOH solution which concentration was checked against 
potassium hydrogenphthalate. The values of E0 were in range 405-415 
mV, while the slope S was about 58.5-59.8 mV.(-log [H+])-1 which agree 
well with expected value for Nernstian slope of glass ion-selective 
electrode. The water ionic product pKw = 13.80 ± 0.02 was determined in 
order to check the correct work of our experimental instrumentation. 
 
 
In vivo studies 
Male Sprague–Dawley and Lang Evans rats (250–300 g) were used for in 
vivo studies. For surgery, animals were anesthetized with 2.0% isoflurane 
(Forene, Abbott, Wiesbaden, Germany) and placed in a stereotaxic frame 
(Kopf Instruments). Local anesthetic xylocain was used additionally for the 
surgery area. Bregma, the sagittal suture, and the surface of the brain 
were used as references for the anterior–posterior (AP), lateral (L), and 
ventral (V) coordinates, respectively. Guiding cannula (OD 360 ID 200) 
was implanted in the place of injection and fixed with dental cement (a 
small hole was drilled for cannula placement). The injections within the 
magnet were done through a 4m long sharpened fused silica capillary (ID 
100µm, OD 160µm), connected with the guiding cannula, placed in the 
brain on the one side and 100 µL Hamilton syringe on the other side. The 
drive for the 50µl Hamilton Microliter Syringes was a modified Kopf 
Micropositioner (Model 650). During the scan, the isoflurane anesthesia 
was reduced to 1.5-1.7%. Rats were immobilized in a non-magnetic 
stereotaxic head holder. The rat body was placed on a heating pad to 
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maintain a body temperature of 37°C. Imaging was ca rried out on a 
vertical 7 T/60 cm MRI Biospec system (Bruker Biospin, Germany). 
 
 
MR methods 
The in vivo diffusion studies were performed on a 7T 300MHz NMR 
System, using a T1 wighted spin echo (SE) sequence with the 
parameters: TR 700ms, TE 20ms, FOV 13x17x0.4 cm, Matrix 256x512, 
Slices 20. 
The in vivo experiments for detection of calcium concentration changes 
during the stimulations were done on a 4.7T 200MHz NMR System. One 
sequence used for a fast T1 measurement have been two segment 
gradient echo (GE), inversion recovery (IR) EPI with following 
parametrers: TR 750ms, TE 8ms, FOV 3.2x2.6x0.1 cm, Matrix 64x52, 
Slices 3, 16 variable inversion delays 15-3000ms, and a temporal 
resolution of ~2min. 
Additionally conventional functional GE EPI as well T1 wighted GE IR EPI 
series with variable parameters have been performed for dedecting 
calcium concentration changes with the CAs. 
 
 
3.2.2. Synthesis of acyclic bifunctional chelates and their 
lanthanide complexes 
 
 
Compound 1 is commercially available and compound 2 was prepared 
according to the literature.194 
 
N1,N3-bis(2-aminoethyl)-5-nitroisophthalamide (3). A suspension of 2 
(5.0 g, 20.9 mmol) in dry methanol (15 mL) was added dropwise to 
ethylendiamine (50 mL) at r.t. with vigorous stirring. Stirring was continued 
for 18 h. Removal of the solvent left a brownish solid, which was dried at 
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50° C in vacuo for 6 h and left at r. t. in vacuo for another 24 h. Yield: 9.80 
g (89 %). 13C {1H} NMR (D2O): δ 39.9, 42.8 (CH2), 124.6 131.7, 135.4, 
147.6, (C6H3),166.3 (CO),. 1H NMR (D2O): δ 2.61 (t, 3JHH = 6.3 Hz, 4H, 
CH2), 3.19 (t, 3JHH = 6.3 Hz, 4H, CH2), 8.03 (s, 1H, C6H3),8.18 (s, 2H, 
C6H3), ES-MS: m/z 296.2 [M + H]+, Calcd for C12H17N5O4 295.3. EA Calcd: 
C 48.61%, H 5.80%, N 23.72%. Found: C 48.00%, H 5.37%, N 23.83% 
 
5-Nitroisophtalamide-bis(ethylamine,N,N’bis-methylacetic acid t-butyl 
ester) (4). Compound 3 (2.95 g 10 mmol) was dissolved in 50 mL of 
acetonitrile. After addition of K2CO3 (5.52 g, 40 mmol) the solution was 
stirred for 30 min at r. t. To this mixture t-butyl bromomethylacetate (8.58 
g, 44 mmol) in 50 mL of acetonitrile was added dropwise and stirred for 18 
h at 70°C.  The inorganic salts were filtered off a nd the solvent was 
removed under reduced pressure. The brown oil was purified by flash 
chromotogrophy using 5% of CH3OH in DCM as an eluent. Yield: 6.53 g 
(86.9 %). 13C {1H} NMR (CDCl3): δ 27.6 (CH3), 47.7, 51.1 55.4, (CH2), 81.5 
(C(CH3)3), 123.6, 132.6, 136.2, 147.8, (C6H3), 164.1(COOtBu),171.1  
(CONH); 1H NMR (CDCl3): δ 1.45 (s, 36H CH3), 2.69 (t, 3JHH = 5.3 Hz, 4H, 
CH2NCO), 3.39 (s, 8H, CH2COOtBu), 3.68 (m, 4H, CH2), 8.64 (s, 1H, 
C6H3), 8.95 (s, 2H, C6H3), ES-MS: m/z 752.9 [M + H]+, Calcd for 
C12H17N5O4 751.9 
 
5-Nitroisophtalamide- bis(ethylamine,N,N’bis-methylacetic acid) (5). 
Trifluoroacetic acid (20 mL) was added carefully to 4 (7.51 g, 10 mmol) 
dissolved in dichloromethane (20 mL). After the mixture had been stirred 
at r. t. for 24 h the solvents were removed under reduced pressure. To 
take out the excess of trifluoroacetic acid dichloromethane (40 mL) was 
added and evaporated off, twice. The same procedure was repeated twice 
with methanol as extracting agent. The viscous residues were taken up in 
a minimum amount of methanol and cold ether was added dropwise. The 
formed precipitate was recrystallized from hot methanol. The yellow to 
brown crystalline powder was filtered off, washed with methanol and dried 
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in vacuo. Yield: 3.66 g (69.5 %). 13C {1H} NMR (D2O): δ 30.2, 35.4, 56.1 
(CH2), 125.5, 132.1, 134.9, 147.9, (C6H3), 168.5 (CONH),169.3 (COOH),. 
1H NMR (D2O): δ 3.51 (m, 4H, CH2NCO), 3.73 (m, 4H, CH2NCO), 4.01 (s, 
8H, CH2COOH), 8.41 (s, 1H, C6H3), 8.62 (s, 2H, C6H3), ES-MS: m/z 528.4 
[M + H]+, Calcd for C12H17N5O4 527.4. EA Calcd: C 43.90%, H 4.52%, N 
12.28%. Found: C 44.21%, H 4.30%, N 11.76%. 
 
N1,N3-bis(2-aminoethyl)-5(phenethoxycarbonyloxyamino)isophthal -
amide (8). Compound 7 (2.09 g, 10 mmol), was dissolved in a solution of 
DCM (20 mL) and water (40mL). The solution was treated with alternating 
addition of a solution of carbobenzoxy chloride (CBz) (1.9 g, 12 mmol) in 
DCM (20 mL), and of 3.5 M K2CO3 with vigorously stirring at room 
temperature. The pH was maintained at 6-7 by dropwise addition. After 
CBz was added over 0.5 h, it was stirred under pH 7-8 for 2 h. White 
precipitate was filtered and recrystallized from ethylacetate to give a white 
powder 3.0 g (88%) yield. 13C {1H} NMR (DMSO): δ 52.4 (CH3),. 66.1 
(CH2), 122.4, 123.3, 128.1, 128.4, 130.6, 136.3, 138.3, 
140.1(C6H3),153.3,165.2 (CONH), 1H NMR (DMSO): δ 3.80 (s, 6H, CH3), 
5.19 (s, 2H, CH2), 7.32 – 7.46 (m, 5H, C6H5), 8.05 (s, 1H, C6H3), 8.32 (s, 
2H, C6H3), 10.20 (s, 1H, NH); ES-MS: m/z 344.3 [M + H]+, Calcd for 
C18H17NO6 343.3 
 
Benzyl3,5-bis(2-aminoethylcarbamoyl)phenylcarbamate (9). 
Compound 9 was synthesized by the similar way as it was described for 
compound 3 starting from 3.0 g (8.75 mmol) of 8. Finally it was 
recrystallized from ethylacetate to give 318 g (91%) of yield. 13C {1H} NMR 
(CDCl3): δ 40.1, 43.5 (CH2), 67.1 (CH2), 122.4 123.3, 128.1, 128.4, 130.6, 
136.3 138.3, 140.1, (C6H3), 153.3,165.2 (CONH), 1H NMR (CDCl3): δ 3.80-
4.60 (m, 8H, CH3), 5.19 (s, 2H, CH2), 7.32 – 7.46 (m, 5H, C6H5), 8.05 (s, 
1H, C6H3), 8.32 (s, 2H, C6H3), 10.20 (s, 1H, NH); ES-MS: m/z 400.3 [M + 
H]+, Calcd for C20H25N5O4 399.4 
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5-Aminoisophtalamide-bis(ethylamine,N,N’bis-methylacetic acid 
 t-butyl ester) (10). Compound 10 was synthesized similar to compound 4 
starting with 3.5 g (8.8 mmol) of 9.  Light brown viscous oil was purified by 
column chromatography from DCM/ MeOH (5%) mixture as mobile phase. 
Yield: 6.53 g (86.9 %). 13C {1H} NMR (CDCl3): δ 27.7 (CH3), 38.6 52.5, 
56.2, 66.9, (CH2), 81.7 (C(CH3)3), 120.3, 120.5, 128.5, 128.8, 136.1, 
136.7, 139.7, 153.9, (C6H3), 162.8, 167.3 (CONH),171.5 (COOtBu); 
1H NMR (CDCl3): δ 1.80 (s, 36H, CH3), 2.50 – 4.00 (m 16H, CH2) 5.19 (s, 
2H, CH2), 7.32 – 7.46 (m, 5H, C6H5), 8.05 (s, 1H, C6H3), 8.32 (s, 2H, 
C6H3); ES-MS: m/z 857.1 [M + H]+, Calcd for C44H65N5O12 856.0 
 
5-Aminoisophtalamide- bis(ethylamine,N,N’bis-methylacetic acid) 
(11). Compound 10 (2.13 g, 2.5 mmol) was taken in ethanol (50 mL) and 
hydrogenated at 30 psi in the presence of 200 mg of Pd/C (10%) for 24 h. 
The catalyst was removed by filtration through Celite and the filtrate was 
concentrated to dryness.  A light brown powder (1.65 g) which was 
obtained dissolved in 5mL of DCM and10 mL of TFA was added to the 
solution. After mixture had been stirred at r.t. for 12 h the solvents were 
removed under reduced pressure. To take out the excess of trifluoroacetic 
acid dichloromethane (10 mL) was added and evaporated off, twice. The 
same procedure was repeated twice with methanol as extracting agent. 
The viscous residues were taken up in a minimum amount of methanol 
and cold ether was added dropwise. The formed precipitate was 
recrystallized from hot methanol. Yield: 0.931 g (73.5 %). 13C {1H} NMR 
(D2O): δ35.7 (CH2), 56.4 (CH2COOH), 56.6 (CH2), 125.1, 125.8, 133.2, 
135.5(C6H3),169.9 (COOH), 1H NMR (D2O): δ 3.44 (m, 4H, CH2NCO), 
3.65 (m, 4H, CH2NCO), 3.96 (s, 8H, CH2COOH), 7.76 (s, 2H, C6H3), 8.00 
(s, 1H, C6H3), ES-MS: m/z 498.5 [M + H]+, Calcd for C20H27N5O10 497.5. 
  
 Complexation with lantanides (6a – b and 12a – b). Compounds 5 and 
11 (1.9 mmol) were dissolved in 30 mL of water, 1.0 eq. of the 
corresponding lanthanide chloride was added to the solution while the pH 
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was adjusted to 5.5 – 6.0. The reaction mixture was stirred at room 
temperature for 12 h. The solutions were filtered and an anion exchange 
resin (Chelex 100) was added to the stirring solution, the suspension was 
filtered after 1 h, syringed through 0.2 µm nylon filters and the solvent 
evaporated. The xylenol test showed the absence of the noncoordinated 
metal ions in the systems. ES-MS: compound 6a – b m/z 681.5 [M + H]+, 
Calcd for GdC20H21N5O12 680.7; m/z 677.1 [M + H]+, Calcd for 
EuC20H21N5O10 675.4; compound 12a – b m/z 651.5 [M + H]+, Calcd for 
GdC20H23N5O10 650.3; m/z 645.4 [M + H]+, Calcd for EuC20H23N5O10 645.2  
 
 
3.1.3. Synthesis of the DO3A based mono(alkylphos- phonate) 
lanthanide complexes 17a – b and 19a - b 
 
 
tri-tert-butyl 2,2',2''-(10-(3-(diethoxyphosphoryl)propyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (15). To the solution of 7 (1 
eq) and K2CO3 (1.5 eq) in 80 mL acetonitrile was added a solution of 
diethyl(3bromopropyl)phosphonate (1.2 eq) in 30 mL of acetonitrile. After 
the reaction mixture was stirred for 12 h at 70°C, the solution was allowed 
to cool to r. t., filtered and concentrated in vacuo to give yellow oil. The oil 
was purified by column chromatography (5% of MeOH in DCM) to give 
78% of the final compound. 1H NMR (CDCl3, 400 MHz): δ (ppm) 0.8 (m, 
6H), 1.02 – 1.08 (m, 27H), 1.21 (m, 4H), 1.26 -3.93 (m, 28H), 13C {1H} 
NMR (CDCl3, 100 MHz): δ (ppm) 173.2, 172.6, 82.7, 82.4, 61.6, 58.2, 
57.3, 56.5, 54,3, 52.2, 51.8, 49.1, 28.1, 27.8, 23.0, 22.1, 16.4. 31P NMR 
(CDCl3): δ (ppm) 33.6. HRMS (EI) for C33H65N4O9P: calc. 693.45619 [M + 
H]+, found 693.45604. 
 
 
2,2',2''-(10-(3-phosphonopropyl)-1,4,7,10-tetraazacyclododecane-
1,4,7-triyl)triacetic acid (16). 
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 To the solution of 15 (1eq) in dry dichloromethane bromtrimethylsilane 
was added slowly at 0°C (10eq) and the mixture was stirred for 12 h at r. t. 
The solvent was removed by evaporation and the residue was dissolved in 
20 mL of the trifluoroacetic acid. After the mixture had been stirred at r. t. 
for 24 h the solvent was removed under reduced pressure. The viscous 
residue was taken up in a minimum amount of methanol and was added 
dropwise into cold ether. The formed precipitates were filtered and 
resuspended in 3 mL of water. Then cold ethanol was added slowly under 
stirring. The solutions were cooled to -20 °C for 1 2 h. The solid product 
was separated by filtration and dried by prolonged standing in vacuo 
yielding 68% of a final product. 13C {1H} NMR (D2O): δ 174.3, 169.6 
(COOH), 57.3, 55.9, 53.1, 51.4, 49.6, 48.3, 48.1, 24.4 (1JPC = 134.7 Hz), 
17.3 (CH2). 1H NMR (D2O): δ 3.8 (s, 3H, CH2COOH), 2.9 – 3.5 (m, 24H,), 
1.8 (br 2H, CH2P), 1.5 (q, 2H,JHH = 8.6 Hz). 31P {1H} NMR (D2O): δ 24.1.  
HRMS (EI) for C17H33N4O9P calc. 496.20563 [M + H]+, found 469.20579. 
 
 
2,2',2''-(10-(3-(diethoxyphosphoryl)propyl)-1,4,7,10-tetraazacyclodo 
decane-1,4,7-triyl)triacetic acid (17). 
Compound 15 (2 mmol) was dissolved in dichloromethane (10 mL) and to 
this solution trifluoroacetic acid (10 mL) was added carefully. After the 
mixture had been stirred at r. t. for 16 h the solvents were removed under 
reduced pressure. To take out the excess of trifluoracetic acid 
dichloromethane (40 mL) was added and evaporated off, twice. The same 
procedure was repeated twice with methanol as extracting agent. The 
viscous residues were taken up in a minimum amount of methanol and 
cold ether was added dropwise. The formed precipitates were filtered, 
washed with acetone and dried in vacuo yielding 72% of a final 
product.13C {1H} NMR (D2O): δ 173.9, 168.9 (COOH), 63.4, 55.1, 53.6, 
52.8, 51.5, 49.7, 48.3, 48.0, 20.9 (1JPC = 141.1 Hz), 16.5 (CH2), 15.6 
(CH3). 1H NMR (D2O): δ 3.7 – 3.9 (m, 7H, CH2COOH and CH2CH3), 2.7 – 
3.4 (m, 24H,), 1.5 – 1.7 (m, 4H, CH2CH2P), 1.1 (t, 6H, JHH = 7.1 Hz, 
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CH2CH3). 31P {1H} NMR (D2O): δ 33.1. HRMS (EI) m/z 525.26909 [M + 
H]+, Calcd for C17H34N4O9P 525.26839. 
 
 
General procedure for the synthesis of lanthanide complexes (17a –b 
and 19a - b). To the water solutions of 1 eq of the ligands 16 and 18, 0.9 
eq of GdCl3 x H2O or EuCl3 x 6H2O was added. The mixtures were heated 
to 60°C for 24 h. The pH was periodically checked a nd adjusted to 6.5 ~ 
7.0 using a 1M solution of NaOH. The reaction mixtures were cooled, 
NaOH was added to bring the pH to 12 and the reaction mixture was 
syringed through 0.2 µm nylon filter to remove the excess of non 
coordinated metal. Anion exchange resin (Chelex 100) was added to the 
stirring solution, suspensions were filtered after 1 h and the solvents 
evaporated. The xylenol test showed the absence of the non-coordinated 
metals in the systems. ES-MS: for the compound 17a m/z 645.2 [M + Na]+, 
Calcd for GdC17H30N4O9P; for the compound 17b 622.4; m/z 618.4 [M + 
H]+, Calcd for  EuC17H30N4O9P 617.2; for the compound 19a m/z 678.8 [M 
+H]+, Calcd for GdC21H38N4O9P 678.8; for the compound 19b m/z 674.8 
[M +H]+, Calcd for EuC21H38N4O9P 673.5; 
 
 
3.1.4. Synthesis of the DO3A based 
amino(bismethylene)phosphonate lanthanide complexes 
 
 
General procedure for N-Boc-3-aminoalkyl bromide (21a – c). A 
solution of NaOH (3 eq.) in 30 mL of water was added dropwise to a 
vigorously stirring biphasic mixture consisting of 20a – c (1.5 eq.) in 50 mL 
of water and Boc2O (1 eq.) in 100 mL of dichloromethane. After 3 h the 
organic phase was separated and washed with 50 mL of a 2N HCl and 50 
mL of a saturated NaCl solution. The organic phase was dried over 
MgSO4 and concentrated in vacuo. To the oil 20 mL of n-hexane was 
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added and the solution was stored at -20° C overnig ht. The products were 
separated from the solvent, washed with cold n-hexane and dried in 
vacuo.  
tert-butyl 3-bromopropylcarbamate (21a): Colorless crystals yield 68%. 
13C {1H} NMR (CDCl3): δ 155.6 (CO), 79.8 (C(CH3)3), 38.6, 32.4, 30.4 
(CH2), 27.9 (CH3). 1H NMR (CDCl3): δ 5.25 (s, 1H, NH), 3.38 (t, 2H, 3JHH = 
6.5 Hz, BrCH2), 3.25 (t, 2H, 3JHH = 6.5 Hz, NHCH2), 1.95 (tt, 2H, 3JHH = 
6.52, 3JHH= 6.52, CH2), 1.37 (s, 9H, CH3). EA Calcd: C 40.35%, H 6.77%, 
N 5.88%. Found: C 40.29%, H 7.23%, N 5.88% 
tert-butyl 5-bromopentylcarbamate (21b): Yellow crystals, yield 65%. 
13C {1H} NMR (CDCl3): δ 158.3 (CO), 79.8 (C(CH3)3), 40.5, 33.8, 32.6, 
29.4 (CH2), 28.7 (CH3), 25.5 (CH2). 1H NMR (CDCl3): δ 4.92 (s, 1H, NH), 
3.52 (t, 2H, 3JHH = 6.74, BrCH2), 3.25 (m, 2H, NHCH2), 1.94 (tt, 2H, 3JHH = 
6.7 Hz, 3JHH = 6.9 Hz, CH2), 1.32 (s, 9H, CH3), 1.25-1.40 (m, 4H, CH2). EA 
Calcd: C 45.12%, H 7.57%, N 5.26%. Found: C 45.16%, H 7.20%, N 
5.49% 
tert-butyl 5-bromohexylcarbamate (21c): Brown oil, yield 62%. 13C {1H} 
NMR (CDCl3): δ 158.6 (CO), 79.9 (C(CH3)3), 40.1, 33.9, 32.8, 30.0 (CH2), 
28.5 (CH3), 27.9, 26.1 (CH2). 1H NMR (CDCl3): δ 4.73 (s, 1H, NH), 3.19 (t, 
2H, 3JHH = 6.8 Hz, BrCH2), 2.94 (m, 2H, NHCH2), 1.65 (tt, 2H,  3JHH = 6.8 
Hz, 3JHH = 7.6 Hz, CH2), 1.24 (s, 9H, CH3), 1.22-1.40 (m, 6H, CH2). EA 
Calcd: C 47.15%, H 7.91%, N 5.00%. Found: C 47.22%, H 7.22%, N 
5.22% 
 
General procedure for tri-tert-butyl 2,2',2''-(10-(3-(tert-butoxycarbonyl 
amino)alkyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate (22a 
- c). To the solution of 1,4,7-tri(t-butoxycarbonylmethyl)cyclen 8 (1 eq.) 
and K2CO3 (1.5 eq.) in 30 mL acetonitrile was added a solution of 21a – c 
(1.1 eq.) in 20 mL of acetonitrile. After the reaction mixture had been 
stirred for 16 h at 70°C, the solution was allowed to cool to r. t., filtered and 
concentrated in vacuo to give a yellow to brown oil. The compounds were 
recrystallised from heptane. 
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tri-tert-butyl 2,2',2''-(10-(3-(tert-butoxycarbonylamino)propyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (22a).  Yellow oil, yield 
85%. 13C {1H} NMR (CDCl3): δ 173.6, 172.6 (COOt-Bu), 156.3 (COBoc), 
82.7, 82.4, 81.7 (C(CH3)3), 57.4, 56.4, 55.7, 51.7, 50.2, 49.7, 38.7 (CH2), 
28.4, 28.0, 27.8 (C(CH3)3), 26.6, 18.3 (CH2), 1H NMR (CDCl3): δ 5.90 
(s,1H, NH), 3.60 – 2.03 (m, 26H, CH2), 1.29 (m, 2H, CH2NH), 1.11 – 1.05 
(m, 36H, C(CH3)3). ES-MS m/z 672.4 [M + H]+, Calcd for C34H65N5O8 
671.9. 
tri-tert-butyl 2,2',2''-(10-(3-(tert-butoxycarbonylamino)pentyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (22b). Yellow oil, yield 
83%.  13C {1H} NMR (CDCl3): δ171.6, 170.7 (COt-Bu), 155.7 (COBoc), 
81.6, 80.2, 78.3 (C(CH3)3), 56.1, 55.9, 53.1, 51.9, 5.6, 51.3, 40.1, 33.3, 
31.8 (CH2) 28.0, 27.7, 27.5 (C(CH3)3), 24.3, 22.8 (CH2). 1H NMR (CDCl3): 
δ 5.22 (s,1H, NH), 3.42 – 1.64 (m, 26H, CH2), 1.36 – 1.32 (m, 36H, 
C(CH3)3), 1.14 – 1.30 (m, 6H CH2).  ES-MS m/z 700.6 [M + H]+, Calcd for 
C36H69N5O8 699.9. 
tri-tert-butyl 2,2',2''-(10-(3-(tert-butoxycarbonylamino)hexyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetate (22c). Brown oil, yield 82%.  
13C {1H} NMR (CDCl3): δ 172.4, 170.8(COOtBu), 155.8 (COBoc), 82.3, 
82.0, 81.6, (C(CH3)3), 56.4, 56.1, 52.2, 51.8, 51.8, 51.6, 40.2, 33.7, 32.4, 
29.8 (CH2), 28.4, 28.0, 27.7(C(CH3)3), 27.6, 26.5(CH2). 1H NMR (CDCl3): δ 
4.83 (s,1H, NH), 2.93 – 1.26 (m, 26H, CH2), 0.83 – 0.89 (m, 36H, 
C(CH3)3), 0.71 (m, 8H CH2).   
HR-FAB m/z 736.52186 [M + H]+, Calcd for C37H71N5O8Na 736.519995.  
  
General procedure for 2,2',2''-(10-(3-aminoalkyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (23a – c). Compounds 
22a – c (2 mmol) were taken in dichloromethane (20 mL) and to these 
solutions trifluoroacetic acid (20 mL) was added carefully. After the mixture 
had been stirred at r. t. for 24 h the solvents were removed under reduced 
pressure. To take out the excess of trifluoracetic acid dichloromethane (40 
mL) was added and evaporated off, twice. The same procedure was 
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repeated twice with methanol as extracting agent. The viscous residues 
were taken up in a minimum amount of methanol and cold ether was 
added dropwise. The formed precipitates were filtered and resuspended in 
3 mL of water. A large excess of acetone (100mL) was added and the 
cloudy solutions were stored at -20 °C for 16 h. Co lorless crystalline 
powders were filtered off, washed with acetone and dried in vacuo. 
2,2',2''-(10-(3-aminopropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid (23a). Colorless crystalline powder, yield 54% 13C {1H} 
NMR (D2O):174.2, 171.2 (COOH), 56.5, 53.8, 51.6, 50.6, 49.7, 48.7, 37.4, 
24.9, 24.9 (CH2). 1H NMR (D2O):  δ 3.69 – 2.66 (m, 26H, CH2), 1.73 (m, 
2H, CH2). HRMS (EI): for C17H33N5O6 Calcd: 408.32653  [M - H]-; found: 
408.326601  
 2,2',2''-(10-(3-aminopentyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid (23b). Colorless crystalline powder, yield 50%. 13C {1H} 
NMR (D2O): δ 174.4, 169.1 (COOH), 55.9, 54.1, 53.2, 51.6, 49.9, 48.5, 
48.3, 39.2, 26.3, 22.9, 22.7 (CH2).  1H NMR (D2O): δ 3.74 (m, 2H, 
CH2NH2), 3.50 – 2.64 (m, 24H, CH2), 1.57 – 1.21 (m, 6H, CH2); HRMS 
(EI): for C19H37N5O6 Calcd: 430.26711 [M - H]-; found: 430.26642 
2,2',2''-(10-(3-aminohexyl)-1,4,7,10-tetraazacyclododecane-1,4,7-
triyl)triacetic acid (23c). Colorless crystalline powder, yield 58%. 13C {1H} 
NMR (D2O): δ 174.4, 170.1 (COOH), 56.3, 54.3, 53.4, 51.5, 49.9, 48.5, 
48.3, 39.4, 26.5, 25.4, 25.3, 22.9 (CH2). 1H NMR (D2O): δ 3.69 (m, 2H, 
CH2NH2), 3.40 – 2.68 (m, 24H, CH2N), 1.61 – 1.12 (m, 8H, CH2). HRMS 
(EI): for C20H39N5O6 Calcd: 444.28276 [M - H]-; found: 444.28282  
 
2,2',2''-(10-(3-(bis(phosphonomethyl)amino)alky)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (25a - c).  Compounds 
23a - c (1 eq.) were dissolved in 10 mL of 6 M HCl. To these solutions 
phosphoric acid (2 eq.) in 5 mL of water was added and the mixtures were 
heated to reflux. Paraformaldehyde (4eq.) was added portionwise within 1 
h and heating under reflux was continued for further 24 h. The reaction 
mixtures were concentrated under reduced pressure and cold ethanol was 
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added slowly under stirring. The solutions were cooled to -20 °C for 12 h. 
The solid product was separated by filtration and dried by prolonged 
standing in vacuo. 
 
2,2',2''-(10-(3-(bis(phosphonomethyl)amino)propyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (25a). Colorless 
powder, yield 54%. 13C {1H} NMR (D2O): δ 173.7, 167.7 (COOH), 54.0 (d, 
1JPC = 33.6 Hz), 52.9, 52.2, 51.5, 51.4, 50.9, 50.7, 50.1, 48.3, 19.4. 1H 
NMR (D2O): δ 2.20 – 3.35 (m, 30H), 1.29 – 1.39 (m, 2H). 31P {1H} NMR 
(D2O): δ 10.02.  HRMS (EI): for C19H39N5O12P2 Calcd: 590.19977 [M - H]-; 
found: 590.19852 
2,2',2''-(10-(3-(bis(phosphonomethyl)amino)pentyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (25b). Colorless 
powder, yield 52%. 13C {1H} NMR (D2O): δ 174.3, 168.4 (COOH), 55.9, 
54.1, 53.8, 52.8, 51.7, 50.5, 49.9, 48.7, 48.1(d, 1JPC = 33.8 Hz), 22.6, 22.5, 
22.3. 1H NMR (D2O): δ 4.01 (m, 2H, CH2N(CH2PO3H2)2), 2.85 – 3.60 (m, 
28H), 1.25 – 1.66 (m, 6H). 31P {1H} NMR (D2O): δ 7.44. HRMS (EI): for 
C21H43N5O12P2 Calcd: 618.23107 [M - H]-; found: 618.23101 
2,2',2''-(10-(3-(bis(phosphonomethyl)amino)hexyl)-1,4,7,10-
tetraazacyclododecane-1,4,7-triyl)triacetic acid (25c). Colorless 
powder, yield 56%. 13C {1H} NMR (D2O): δ 174.3, 168.7 (COOH), 56.6, 
54.9, 54.3, 53.0, 52.2, 51.9, 50.8, 50.2, 48.2 (d, 1JPC = 33.8 Hz), 25.3, 
25.0, 23.2, 22.68. 1H NMR (D2O): δ 3.96 (m, 2H, CH2N(CH2PO3H2)2), 2.75 
– 3.31 (m, 28H), 1.53 (m, 4H), 1.18 (m, 4H). 31P {1H} NMR (D2O): δ 10.23. 
HRMS (EI): for C22H45N5O12P2 Calcd: 632.24672 [M - H]-; found: 
632.24670 
 
General procedure for the synthesis of Ln- complexes (Gd 24a – c, 
26a - c and Eu 27a – c).To the water solutions of 1equivalent of the 
ligands 23a – c and 25a – c  0.9 to 1.0 equivalent of the corresponding 
LnCl3 was added. The mixtures were heated to 90°C for 24 h. The pH was 
periodically checked and adjusted to 6.5 ~ 7.5 using a 1M solution of 
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NaOH. After 24 h the reaction mixture had been cooled, NaOH was added 
to bring the pH to 12. The reaction was syringed through 0.2 µm nylon 
filters to remove the excess of Ln3+. An anion exchange resin (Chelex 100) 
was added to the stirring solution, the suspensions were filtered after 1 h 
and the solvent evaporated. The xylenol test showed the absence of the 
non-coordinated metal ions in the systems. ES-MS: for the compound 26a 
m/z 746.7 [M + H]+, Calcd for GdC19H36N5O12P2 745.6; for the compound 
26b m/z 773.9 [M - H]+, Calcd for  GdC21H40N5O12P2 773.8; for the 
compound 26c m/z 789.1 [M +H]+, Calcd for GdC22H42N5O12P2 787.9; for 
the compound 27a m/z 741.6 [M +H]+, Calcd for EuC19H36N5O12P2 740.4; 
27b m/z 769.7 [M +H]+, Calcd for EuC21H40N5O12P2 768.5; for the 
compound 27c m/z 783.4 [M +H]+, Calcd for EuC22H42N5O12P2 782.5; 
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ABSTRACT 
 
 
Magnetic Resonance Imaging (MRI) is a diagnostic scanning technique 
based on the principles of nuclear magnetic resonance. It is a method of 
obtaining images of the body in thin slices. Functional magnetic resonance 
imaging (fMRI) is based on Blood-Oxygen-Level-Dependent (BOLD) 
contrast. It is currently the mainstay of neuroimaging, whose ever growing 
applications provide a wealth of information regarding the processes in the 
brain. The chief disadvantages of BOLD-fMRI are its limited temporal and 
spatial resolution. In fact, BOLD imaging as well as other fMRI methods 
alone is insufficient for a detailed study of the neural networks that 
underlie human or animal cognition.  
In general MRI measures the signal from the hydrogen nuclei of water 
which can be modified by the chemical environment. This signal intensity 
and therefore, contrast of the image depends essentially on three factors: 
the density of proton spins in a given volume and the longitudinal and 
transverse relaxation times T1 and T2 of these spins. The relaxation times 
may be shortened considerably in the presence of paramagnetic species 
which are called contrast agents. While both organic and inorganic 
radicals can be MRI contrast agents, this work is restricted to 
gadolinium(III) containing agents. The lanthanide ion gadolinium(III) is 
generally chosen, because it has a high magnetic moment, and the most 
unpaired electrons of any stable ion. But because of the high toxicity of 
gadolinium, it must be chelated with organic molecules to form a strong 
seven to eight coordinated complex which will be less toxic, while having 
one or two coordination sites free for interaction with water molecules. 
The aim of the present work is to develop contrast agents which are 
‘smart’ biochemical functional markers that detect neuronal activity in real 
time and translate it into changes in MR contrast. That can be 
temperature, pH, pO2, presence of aminoacids and proteins or changes in 
the concentration of any cations and anions involved in the process of 
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neuronal activity. Since calcium plays an important role in neuronal 
processes in present work pH and calcium sensitive contrast agents have 
been developed. Therefore, a series of gadolinium based complexes have 
been designed, synthesized and characterized. Finally in vivo 
investigations of the compounds have been preformed by combined 
electrophysiological and fMRI methods. 
Acyclic bifunctional chelating agents 1 and 2 were synthesized by two 
different ways starting from the dimethylester of nitro- or aminoisophtalic 
acid.  
 
 
.  
 
 
 
 
 
Chart 1.  Bifunctional chelating agent. Z = -NO2(1), -NH2(2) 
 
 
Complexes with gadolinium and europium were obtained and relaxivities 
were measured at 300 MHz and 25oC. The very poor solubility of the 
complexes in water and most organic solvents indicate the formation of di- 
or polymer chains upon the complexation. This makes the complexes 
useless for further investigations as MRI contrast agents. Although the 
amino derivative can be modified and used as a building blocks in the 
syntheses of the specific chelators. 
The second set of compounds was designed to be sensitive to changes of 
pH. The DO3A molecule which is known to form stable complexes with 
lanthanides was used as a base for the synthesis of macrocyclic 
monophosphonates (Chart 2). The choice of phosphonate groups was due 
to their protonation constants which are in slightly acidic/neutral range  
Z
OO
NH HN
N NHOOC
HOOC
COOH
COOH
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(pK = 6-7) and the ability to form strong hydrogen bonds with water 
molecules, which are sensitive to changes of pH. That could lead to 
possible changes in the number of inner/secondary/outer sphere water 
molecules of the lanthanide complex, and therefore its relaxivity 
properties. Protected and unprotected phosphonates 3 and 4 were used to 
study the effect of the charge and acidity of the complexes on the 
relaxivity.  
 
N
N N
N
OO
O
O-
-O
-O
R
Gd3+
 
 
Chart 2. Macrocyclic phosphonate containing compounds. 
  3, R = PO3H2; 4, R = PO3Et2. 
 
Thermodynamic investigations of the ligands have been performed using 
glass-electrode potentiometric titrations and protonation constants of the 
phosphonates as well as stability constants of the ligand-calcium(II) 
complexes (as model for the stability of gadolinium(III) complexes) have 
been determined. pK values of the phosphonic functional groups increase 
with increase of the chain length of the pendant arm. The reverse behavior 
was observed for the second protonation constant of the nitrogen atom of 
the cyclen rim. Relaxometric measurements of the gadolinium(III) 
complexes have been performed at various magnetic fields (20, 60 and 
300 MHz) and different pH of the water solutions (pH 4-10). The most 
interesting result was obtained at acidic pH where relaxivity of the 
complexes 3 and 4 increased by 23% and 60% respectively, when the pH 
of the medium has changed from neutral to pH 4 (20 MHz). The 31P NMR 
studies of the europium complexes supported by the data of 
potentiometric titration demonstrated that the compounds 3 and 4 are 
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stable in the range of pH 4 to 10. Slow decomplexation of complexes is 
observed at pH < 3. This means that the changes of the relaxivity are not 
due to the decomplexation of the compounds.  
Amino(bismethylene)phosphonates are well known for there affinity toward 
calcium. In order to design complexes which will be sensitiv to changes of 
extracellular calcium concentrations a series of macrocyclic compounds 
with variable length of the amino(bismethylene) phosphonates containing 
side chain were synthesized and characterized (Chart 3).  
N
N N
N
O
O
-O
N
n PO3H2
PO3H2
O-
O
-O
Ln3+
 
 
Chart 3. Macrocyclic compounds with the variable length of the side 
chain  5a – b, n = 1; 6a – b, n = 3: 7a – b, n = 4 (Ln3+ = Gd3+(a), Eu3+ (b)) 
 
The compounds were synthesized by the alkylation of the tert-butyl ester 
of DO3A with the corresponding Boc protected bromoalkylamines. After 
the cleavage of the protection groups, phosphonates were introduced by 
Mannich reaction with phosphorous acid and formaldehyde at 100oC. The 
relaxivity studies of the compounds were preformed at high field (300 
MHz). The T1 relaxation time of water was measured for the contrast 
agents 5a
 
– 7a while varying the concentrations of Ca
2+ 
ions. No significant 
changes of the water relaxivity of 5a
 
were found over the whole span of 
Ca
2+ 
concentration. Interestingly, the water relaxivity of 6a
 
solutions which 
remained constant in Ca
2+ 
concentrations from 0 to 1.0 mM dropped from 
3.49 to 2.56 mM
-1
s
-1 
when the Ca
2+ 
concentration was increased to 10 mM. 
More importantly in solutions of the 7a major effect of the change in 
relaxivity was shifted to Ca
2+ 
concentration range which is covering the 
physiologically relevant area. A maximum decrease in r1 of 36% within the 
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physiological range was observed, which was only slightly reduced in 
artificial cerebrospinal fluids (CSF). 
The differences of the 
31
P chemical shifts of the 6b
 
and 7b
 
complexes 
compared to their free ligands indicates that the phosphonate groups were 
not coordinated to europium, while the chemical shift difference of 20 ppm 
in the case of 3b
 
points to an interaction between the metal center and the 
phosphonate functions. Interestingly, the 
31
P resonances of 5b
 
are not 
affected by the addition of Ca
2+ 
ions whereas the line widths increased 
dramatically when the Ca
2+ 
concentration was increased in the solutions of 
6b and 7b, respectively. These results are in line with the relaxivity studies 
of the corresponding gadolinium complexes.  
In vivo experiments show that the compounds are not toxic and could be 
used for in rat investigations. Unfortunately the analysis of the in vivo in 
the rat experiments showed that no changes in T1 upon stimuli did occur.  
